



BI FLORIDA

CELEBRATING 10 YEARS OF
BIOSCIENCE GROWTH IN FLORIDA



OCTOBER 15 - 17, 2007
HYATT REGENCY BONAVENTURE, WESTON, FL

THIS BEATS CASUAL FRIDAYS 1000 TO 1.

Give yourself and your employees a reason to get up in the morning.

If you're looking to build, expand or relocate your business, there's a quality of life in Palm Beach County that's unmatched.

We work in a sophisticated, supportive business environment with a strong communications infrastructure and business incentives.

We offer a skilled, educated and motivated workforce: people who are genuinely happy to be here living and working.

And when it comes to playtime or just plain old R&R, this vacation hotspot is yours to savor 365 days a year.



Palm Beach County, Florida

The proposed home of the
Max Planck Society in the United States.

For information and assistance with
relocating or expanding your business in
Palm Beach County, Florida, contact:

**Business
Development
Board**

PALM BEACH COUNTY'S BUSINESS RESOURCE

561-835-1008

relocations@bdb.org • www.bdb.org

The Business Development Board is the official economic development organization of
Palm Beach County and an Enterprise Florida partner.

Published For:

BioFlorida, Inc.
Phone: (561) 653-3839
Fax: (561) 653-3840

The Esperante Building
222 Lakeview Avenue, 4th Floor
West Palm Beach, FL 33401
admin@bioflorida.com
www.bioflorida.com

Staff

C. Russell Allen, President & CEO
Linda Bonafede, Director of Operations
Stacey Silver, Director of Marketing & Membership

2007 Annual Conference Chair

Mel Rothberg, President & CEO
Rothberg Associates, Inc.

About BioFlorida

Established in 1997 as a non-profit bioscience organization, BioFlorida has grown with the industry, working for and with companies and individuals ranging from Fortune 1000 corporations to small start-up companies. As the statewide association for the bioscience industry, BioFlorida not only supports the creation of state chapters but provides management and marketing services to its regional chapters that cover the Northwest, Northeast, Central, Western and Southeast regions of FL.

BioFlorida Chapters

Northwest Chapter

Northeast Chapter

Central Chapter

Western Chapter

Southeast Chapter

Published & Produced By:

Martonick Publications, Inc.
Toll Free Phone: (866) 387-0967
Toll Free Fax: (866) 458-6557

4703 NW 53rd Ave - Suite B2
Gainesville, FL 32606
info@martonickpublications.com
www.martonickpublications.com

President: Maria Martonick
Managing Editors: Christiana Lilly
Account Executive: Maria Martonick
Graphic Design: Javier Espinosa

©2007 Martonick Publications. All rights reserved.
The contents of this publication may not be reproduced by any means, in whole or in part, without the prior written consent of the publisher.

Please recycle where facilities exist.



BIOFLORIDA

OCTOBER 15 - 17, 2007
HYATT REGENCY BONAVENTURE, WESTON

CONTENTS

- 02 Welcome / President's Message
- 03 BioFlorida Board of Directors
- 04 Exhibitor Booth Locations
- 05 Exhibit Hall Diagram
- 06 Conference Center Diagram
- 16 Sponsors
- 07 BioFlorida Conference Program 2007
- 13 Session Descriptions
- 25 Keynote Spotlight
- 30 Biographies
- 28 Policy Issues

AD INDEX

Affiliated Engineers	53	Reynolds, Smith and Hills	48
Akerman Senterfitt	31	Ruden McClosky	41
Alexandria Real Estate Equities	67	Saliwanchik Lloyd & Saliwanchik	33
AMI - American Meetings	60	SEBIO	34
BIO - Biotechnology Industry Organization	46	Skanska USA Building	78
Bridge Global Pharmaceutical Services	58	Southern Research	77
Burnham Institute for Medical Research	53	Suffolk Construction	34
Burrill & Company	26	The Research Parks at FAU / FL Atlantic Research and Development Authority	65
Business Development Board of Palm Beach County	IFC	The Whiting-Turner Contracting Company	72
Business Wire	79	UF Office of Technology Licensing -UF Tech Connect	40
Compass Strategies	80	UF Sid Martin Biotechnology Incubator	78
Christopher & Weisberg	15	UK Trade & Investment	56
Darby & Darby	48	University of Central Florida	27
Doe and Ingalls of North Carolina	77	University of Miami	72
Edwards Angell Palmer & Dodge LLP	47		
Enterprise Florida	39		
Eos Lifesciences	72		
Fisher Scientific	IBC		
Florida Biologix	72		
Florida Pipette Calibrations	53		
Florida SBDC Network	54		
Florida Trend	59		
Fuerst Humphrey Littleman	44		
Full Spectrum Media	79		
Goodwin Biotechnology	58		
Gresham, Smith & Partners	43		
H. Lee Moffitt Cancer Center & Research Institute	46		
H.I.G. Ventures	41		
JSA of South Florida	78		
Lott & Friedland	49		
Metro Orlando Economic Development Commission	XX		
Nature Magazine	53		
Nova Southeastern University	78		
Pappas Ventures	BC		
Pfizer	37		
Phase 3 Properties	71		

WELCOME President's Message



C. Russell Allen
President & CEO

Welcome Industry Professionals

Ten years ago, BioFlorida was a small organization with a big idea: to create a vehicle of dialogue for the voices of Florida's bioscience industry. At the time, BioFlorida had no staff, was headed by volunteer members and pulled together the

first Annual Conference with about 70 attendees. The bioscience sector, particularly in Florida, was merely a fledgling industry. We've come a long way since then, with an established staff and dozens of members and partners in the field. BioFlorida has also conquered the geographical challenge the state presents and created five official chapters.

One thing that hasn't changed about BioFlorida is its mission: to serve the needs of Florida's bioscience community. During my first year at BioFlorida, my immediate focus was to go out and meet members one-on-one throughout the state and learn about their particular issues and concerns. We started out catching up to the momentum in the industry, and now we're going to lead it. The state has already demonstrated its commitment to biosciences, and we have an opportunity to move Florida into a leading national role and take our research advancements and technologies into the global marketplace.

This year's conference reflects the journey that BioFlorida has taken over the last 10 years. We will discuss current policy issues within the industry and its economic impact on Florida. Our keynote speaker, G. Steven Burrill, will share his perspective on biotechnology and what role Florida will play. In many of the sessions, industry professionals will learn about scientific advances and tools and resources available to grow their businesses. Finally, coming full circle, we will tip our hats to the individuals who started it all a decade ago.

We'll also celebrate the continued growth and momentum of this field — for BioFlorida wouldn't be here without it. Bioscience, health-related and lifestyle-related industries are going to

lead the next wave of our economy. As that occurs, BioFlorida is here to assure that Florida's contribution to that effort remains strong and recognized.

As you move forward and grow, know that BioFlorida is doing the same alongside you.

Sincerely Yours,

C. Russell Allen

C. Russell Allen is President and CEO of BioFlorida and leads the organization to meet the demands of Florida's growing bioscience industry. Russell began his professional career selling and marketing laboratory research equipment and supplies to the bioscience industry in the San Francisco Bay area. He moved from biotechnology sales to the high-tech sector in Atlanta, and in 1996 co-founded Newton Park, Inc., one of the region's most successful and respected new media agencies. As CEO, Russell led the organization from start-up to one of the fastest growing companies and top five agencies in Atlanta.

In 2001, Russell founded iQuotient, parent to the bioscience business consulting and marketing firm, BioQuotient. BioQuotient activities took Russell to his position as Vice President of Bioscience Industry Development at the Metro Atlanta Chamber of Commerce where he led the strategy to support and grow the Georgia bioscience industry, attracted new companies to the state, successfully bid for the BIO annual convention for 2009, and helped introduce numerous legislative initiatives in support of the industry.

Prior to BioFlorida, Russell was President and CEO of BioSouth, Inc., a nonprofit membership organization for the southern U.S. bioscience industry, dedicated to support of commercialization, licensing and partnering efforts across the region. Russell organized the organization's annual conferences, BioFusion and the CDC Technology Forum, and instituted member programs to help facilitate global partnerships for southern life science companies and institutions.

Russell received a bachelor's degree in biology from Pepperdine University and a certificate in Biotech Enterprise Management from the Owen Graduate School of Business at Vanderbilt University.

2007 BOARD OF DIRECTORS

2007 Executive Committee

Thomas H. McLain, Chairman**M. Camila Cote, Treasurer**

Audit Senior Manager
Ernst & Young, LLP

Gregory A. Nelson, Esq., Secretary & Legal Counsel

Shareholder
Akerman Senterfitt

C. Russell Allen, President & CEO

BioFlorida, Inc.

David L. Day

Director, Office of Technology Licensing
Director, Sid Martin Biotechnology Incubator
University of Florida

Weaver Gaines

Vice President and Managing Director
Americas Biotech Distributor

David J. Gury,**President**

Gury Consulting, LLC

Harry Orf, PhD

Vice President for Scientific Operations and Professor of
Chemistry
The Scripps Research Institute – Scripps Florida

Sue Washer

President & CEO
Applied Genetic Technologies Corporation

2007 Board of Directors

Rod Casto, PhD

Associate Vice President for Research, Executive Director
USF College of Medicine

Leslie J. Croland, P.A.

Partner
Edwards Angell Palmer & Dodge LLP

Aaron Davidson

Managing Director
H.I.G. Ventures

John A. Fraser

Executive Director, Office of IP Development &
Commercialization
Florida State University

Richard Hall

President
ACC Hall International – Biolnsure

Richard A. Houghten, PhD

President
Torrey Pines Institute for Molecular Studies

Patrick Kelly

Vice President, State Government Relations
Biotechnology Industry Organization

Kenneth B. Kirby

President
TransDermal Technologies, Inc.

Howard J. Leonhardt

Chairman & CEO
BioHeart, Inc.

Frederick Lippman, R.Ph, Ed.D

Chancellor Health Professions Division
Nova Southeastern University

Joel Marcus

Chief Executive Officer
Alexandria Real Estate Equities, Inc.

Gary Margules

Assistant Provost
University of Miami
Office of Technology Transfer

John Mason

President
BioONE

James J. Mulé, PhD

Associate Center Director
H. Lee Moffitt Comprehensive Cancer Center & Research
Institute

Thomas O'Neal, PhD

Associate Vice President for Research
University of Central Florida

James E. Patrick

Founding Shareholder & CEO
National Healing Corporation

Edward A. Pesicka

Vice President & General Manager
Fisher Scientific Research

Shirley Pomponi, PhD

President & CEO
Harbor Branch Oceanographic Institution

Troy J. Rillo, Esq.

Managing Director
Cornell Capital Partners

Mel Rothberg

President & CEO
Rothberg Associates, Inc.

David R. Saliwanchik

Registered Patent Attorney
Saliwanchik, Lloyd & Saliwanchik

Jack Sullivan, Jr.

President & CEO
Florida Research Consortium

Claire Thuning-Roberson

Vice President, Product Development
Altor Bioscience

Rasesh H. Thakkar

CEO
Tavistock Group

William Warren

CEO
VaxDesign, Inc.

Brenda Workman

Director, Retention, Manufacturing & Life Sciences
Enterprise Florida, Inc.

Anita C. Wright


Associate Professor
Food Science and Human Nutrition Department
University of Florida

EXHIBITOR Booth Locations



Affiliated Engineers, Inc.	135
Akerman Senterfitt	119
AMI - American Meetings, Inc.	121
BE&K Building Group	114
Bridge Global Pharmaceutical Services, Inc.	107
Burnham Institute for Medical Research	127
Business Wire	101
Christopher & Weisberg, P.A.	138
Darby & Darby P.C.	112
Doe and Ingalls of North Carolina	129
Edwards Angell Palmer & Dodge LLP	120
Effective Research	139
Eos Lifesciences, LLC	137
Fisher Scientific	126
Florida Biologix	106
Florida Pipette Calibrations	104
Florida Trend	124
Goodwin Biotechnology, Inc.	103
JSA of South Florida	136
Metro Orlando Economic Development Commission	102
Nature Magazine	133
Nova Southeastern University	116
Phase 3 Properties, Inc.	118
Reynolds, Smith and Hills, Inc.	113
Ruden McClosky	140
Saliwanchik Lloyd & Saliwanchik	123
Skanska USA Building Inc.	134
Suffolk Construction	105
The Research Parks at FAU - FL Atlantic Research and Development Authority	130
The Whiting-Turner Contracting Company	125
UF Office of Technology Licensing - UF Tech Connect	122
UF Sid Martin Biotechnology Incubator	115
UK Trade & Investment	117
University of Miami	128


EXHIBITOR Floor Plan



CONFERENCE Center Diagram



Poolside Reception



BIOFLORIDA CONFERENCE Program 2007

Time	Event	Location
MONDAY, OCTOBER 15, 2007		
Noon – 5:00 PM	Golf Tournament	Bonaventure Country Club
3:00 – 6:30 PM	Registration Open	Conference Center
5:30 – 7:30 PM	Welcome Cocktail Reception	Conference Center Atrium
	Sponsored by UK Trade & Investment and Enterprise Florida	
TUESDAY, OCTOBER 16, 2007		
7:30 – 8:30 AM	Registration Open & Continental Breakfast	Conference Center / Global Ballroom
8:30 – 9:15 AM	<p>Welcome Address: Mel Rothberg 2007 Annual Conference Chair</p> <p>Plenary Panel Session <i>What's Next for Florida's Bioscience Investments</i> Richard A. Lerner, MD President, The Scripps Research Institute Richard A. Houghten, PhD President, Torrey Pines Institute for Molecular Studies John C. Reed, MD, PhD President and CEO, Burnham Institute for Medical Research</p> <p>Sponsored by Saliwanchik, Lloyd & Saliwanchik</p>	Global Ballroom
9:15 – 9:30 AM	Break	
9:15 AM – 6:15 PM	Exhibit Hall & Refreshment Center Open	Grand Ballroom A-D
	<p>BUSINESS <i>Building a Strong Management Team</i> Attracting the talent needed to grow your business.</p> <p>Moderator: Mick Lasher, Lasher Associates Panelist: Carolyn Donaldson, Noven Pharmaceuticals Stephanie Finnegan, Goodwin Biotechnology Navroze S. Mehta, NovaVision</p>	Amphitheater
	<p>SCIENCE <i>Molecular Pathogenesis</i> Basic and clinical research related to the treatment and pathogenesis of underlying disease states.</p> <p>Moderator: Nicholas A. Zachariades, Akerman Senterfitt Panelist: Michael Kolber, University of Miami Miller School of Medicine Sukhvir Mahal, The Scripps Research Institute – Scripps Florida Claes Wahlestedt, The Scripps Research Institute – Scripps Florida</p>	Key West

	<p>RESOURCES</p> <p><i>What's in Your Petri Dish?</i> Discover how your company can receive dollars to train your employees, find pools of highly skilled professionals, advertise open positions at no cost, and access state-of-the-art recruiting, interviewing and assessment tools.</p> <p>Moderator: Doug Sáenz, Workforce Alliance Panelist: Renée Benton, Tampa Bay Workforce Alliance Mimi Coenen, Workforce Alliance Kim Tesch-Vaught, Florida Works Marsha Thrower, Workforce Alliance</p>	FL Ballroom C
	<p>MEMBER ROUNDTABLE</p> <p><i>Medical Device Executives</i> Issues specific to the medical device & technology and diagnostic markets. Limited to senior medical device executives.</p>	President's Boardroom
10:45 - 11:00 AM	Break	
11:00 - 12:15 PM	<p>BUSINESS</p> <p><i>Foreign Patent Filing Considerations & Strategies</i> Protecting intellectual property in foreign markets.</p> <p>Moderator: John Christopher, Christopher & Weisberg Panelist: Paul Burgess, Johnson & Johnson Christopher Eisenschenk, Saliwanchik Lloyd & Saliwanchik John Lucas, Metabasis Therapeutics</p>	Amphitheater
	<p>SCIENCE</p> <p><i>Biomarkers</i> The role of biomarkers in R&D advancements.</p> <p>Moderator: Ken Kirby, TransDermal Technology Panelists: Gary Ascani, Banyan Biomarkers David Seo, University of Miami Miller School of Medicine</p>	Key West
	<p>RESOURCES</p> <p><i>SBIR/STTR Grants</i> NIH and NCI grant funding opportunities and resources.</p> <p>Moderator: Stanley Satz, Bio-Nucleonics Panelist: Jo Anne Goodnight, National Institutes of Health Andrew J. Kurtz, National Cancer Institute</p>	FL Ballroom C
	<p>MEMBER ROUNDTABLE</p> <p><i>Real Estate & Facilities</i> Issues specific to the design and development of bioscience facilities. Limited to developers, architects, builders and other real estate professionals.</p> <p>Panelists: Warner Bonner, Phase 3 Properties Mark Hefferin, BE&K Building Group Jeff Talka, Gresham Smith & Partners</p>	President's Boardroom
12:30 - 1:45 PM	Luncheon & Keynote Address	Global Ballroom
	<p><i>Biotech 2007: A Global Transformation</i> G. Steven Burrill CEO, Burrill & Company</p> <p>Sponsored by Alexandria Real Estate Equities</p>	
1:45 - 2:00 PM	Break	

2:00 - 3:15 PM

BUSINESS

Partnering & Licensing

How to identify, develop and close successful partnership agreements

Moderator: Jon Lourie, Edwards Angell Palmer & Dodge

Panelist: Abel De La Rosa, Pharmasset
Stephen G. Nappi, Florida Atlantic University
Peter Policastro, The Scripps Research Institute
– Scripps Florida

Amphitheater

SCIENCE

Strategic Outsourcing

Using contract research organizations.

Moderator: Gary Margules, University of Miami

Panelists: Eugenio A. Cefali, Eos Lifesciences
Boris Reznik, bioRASI
Sondra Smyrnios, Eos Lifesciences
Bin Yan, Wallace H. Coulter Center for Translational Research,
University of Miami

Key West

RESOURCES

Building Bridges: Connecting Community Colleges, Universities and Workforce

Florida bioscience programs and degrees, and relationships between departments and institutions.

Moderator: Heather Belmont, Miami Dade College

Panelist: Kelly Gridley, Santa Fe Community College
Libby Handel, Palm Beach Community College
Sharon Isern, Florida Gulf Coast University
Jennifer McCafferty-Cepero, University of Miami Miller School of Medicine
Richard Snyder, Florida Biologix

FL Ballroom C

MEMBER ROUNDTABLE

Bio/Pharma Executives

Issues specific to the biotechnology, drug development and pharmaceutical markets. Restricted to senior bio/pharma executives.

President's Boardroom

3:15 - 3:30 PM

Break

3:30 - 4:45 PM

BUSINESS

Reimbursement

How to use reimbursement strategies and considerations for a successful new product launch.

Moderator: Michael P. Levinson, Hogan & Hartson

Panelist: Russel Allinson, Therigy
Stuart M. Langbein, Hogan & Hartson

Amphitheatre

SCIENCE

Neurological Disorders

Cellular, proteomic, therapeutic and drug discoveries related to neurological disorders.

Moderator: Ken Kirby, TransDermal Technologies

Panelist: Mary Bunge, University of Miami

Key West

RESOURCES

State Funding & Incentives

State funding mechanisms and tax incentives for business attraction, growth & retention.

FL Ballroom C

	<p>Moderator: Kelly Smallridge, Business Development Board of Palm Beach County</p> <p>Panelist: Warner Bonner, Phase 3 Properties Katherine McCray, CBIZ Accounting, Tax & Advisory Services Brenda Workman, Enterprise Florida</p>	
	<p>OPEN ROUNDTABLE</p> <p>Education & Workforce How to grease the communication lines between what colleges & universities are teaching and what industry needs.</p> <p>Panelists: Merrill Irving, Miami-Dade College Mike Nicoletta, Medtronic Richard Snyder, Florida Biologix</p>	President's Boardroom
4:45 - 5:00 PM	Break	
5:00 - 6:15 PM	<p>BUSINESS</p> <p>Important Patent Stuff No One Tells You Coordination of FDA and patent matters for terms, extensions and exemption from patent infringement.</p> <p>Moderator: Michael J. Keller, Lott & Friedland</p> <p>Panelist: Reza Ghafoorian, Hansen Huang Technology Law Group Robert Hansen, Hansen Huang Technology Law Group Stanley A. Kim, Ruden McClosky</p>	Amphitheater
	<p>SCIENCE</p> <p>Cardiovascular & Vascular Diseases Basic science and clinical research related to the diseases of the vascular system.</p> <p>Moderator: Franklin Garcia-Godoy, Nova Southeastern University</p> <p>Panelist: Larry Lemanski, Florida Atlantic University Howard J. Leonhardt, BioHeart Steven Lipshultz, University of Miami</p>	Key West
	<p>MEMBER ROUNDTABLE</p> <p>Corporate Finance Issues specific to the financial operation of bioscience companies. Limited to senior corporate finance professionals.</p> <p>Moderator: Teresa Heal, Applied Genetic Technologies Corporation</p>	President's Boardroom
6:15 - 8:15 PM	<p>BioFlorida Dinner Reception</p> <p>Sponsored by Phase 3 Properties</p>	Bonaventure Pool Area

WEDNESDAY, OCTOBER 17, 2007

7:30 – 8:30 AM	Registration Open & Continental Breakfast	Conference Center / Global Ballroom
8:30 – 9:15 AM	<p>Plenary Panel Session:</p> <p>Sponsored by Akerman Senterfitt</p> <p><i>Issues and Policy in Pharma, Biotech & Device</i></p>	Global Ballroom

	<p>Moderator: Elizabeth Goodman Associate Director, State Government Affairs, Genentech</p> <p>Patrick Kelly Vice President of State Government Relations, Biotechnology Industry Organization (BIO)</p> <p>Christopher Badgley Vice President of State Government Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA)</p> <p>Thomas Tremble Associate Vice President, Government & Regional Affairs, Advanced Medical Technology Association (AdvaMed)</p>	
9:15 - 9:30 AM	Break	
9:15 AM – 12:30 PM	Exhibit Hall & Refreshment Center Open	Grand Ballroom A-D
9:30 - 10:45 AM	<p>BUSINESS</p> <p><i>Navigating the FDA</i> Obtaining approval, navigating post-approval hurdles and perspectives on safety.</p> <p>Moderator: Mitchell S. Fuerst, Fuerst Humphrey Ittleman Panelist: William M. Egan, PharmaNet Consulting Christine Humphrey, Fuerst Humphrey Ittleman Bill Wardell, Wardell Associates International</p>	Amphitheater
	<p>SCIENCE</p> <p><i>Cancer Research</i> Diagnostic, clinical and therapeutic approaches</p> <p>Moderator: Nicholas A. Zachariades, Akerman Senterfitt Panelist: David Binninger, Florida Atlantic University Srikumar P. Chellappan, H. Lee Moffitt Cancer Center and Research Institute Eckhard R. Podack, University of Miami Miller School of Medicine</p>	Key West
	<p>RESOURCES</p> <p><i>Redefining the Cluster: Florida's Research Parks, Incubators and Facilities</i> Current and future facility developments and resources for wet labs, manufacturing and support.</p> <p>Panelists: Scott Ellington, Florida Atlantic Research and Development Authority Patti Breedlove, UF Sid Martin Biotechnology Incubator Patrick Kay, Alexandria Real Estate Equities Rasesh Thakkar, Tavistock Group</p>	FL Ballroom C
	<p><i>BioFlorida Board Meetings</i> Restricted to current BioFlorida board members.</p>	
10:45 - 11:00 AM	Break	
11:00am - 12:15 PM	<p>BUSINESS</p> <p><i>Raising Capital</i> Raising funds from angels and venture capital.</p> <p>Moderator: David L. Day, University of Florida Panelists: Art Pappas, Pappas Ventures Michael Wasserman, H.I.G. Ventures Rhys L. Williams, New World Angels Hing C. Wong, Altor Bioscience</p>	Amphitheater

	<p>SCIENCE</p> <p><i>Stem Cell Research</i> Latest advancements in embryonic and adult stem cell research. Moderator: Gary Margules, University of Miami Panelist: Joshua M. Hare, University of Miami Miller School of Medicine Paul C. Schiller, University of Miami Miller School of Medicine</p>	Key West
	<p>RESOURCES</p> <p><i>Florida Going Global</i> Case studies and resources to expand your business internationally. Moderator: Mike Fisher, UK Trade & Investment Panelist: Mary Freeman, Awareness Technology Guy L. Mayer, Tutogen Medical Margaret J. McLaren, Carey Rodriguez Greenberg & Paul</p> <p><i>BioFlorida Strategic Planning Discussions</i> Restricted to current BioFlorida board members.</p>	FL Ballroom C
12:15 - 12:30 PM	Break	President's Boardroom
12:30 - 1:45 PM	<p>Luncheon, Closing Remarks & Special Announcements</p> <p>Impact of Biosciences on Florida's Economy Brian Agnew Assistant Director for Economic & Policy Research, Pfizer</p> <p>The Next 10 Years: BioFlorida's Role C. Russell Allen, President & CEO, BioFlorida</p> <p>The Next 10 Years: BioFlorida's Role</p>	Global Ballroom
1:45 PM	Adjourn	

**Speakers subject to change*

SESSION Descriptions

BUSINESS TRACK

Location: Amphitheater

Business Track sessions will run all day Tuesday, October 16 from 9:30 am – 6:15 pm and on Wednesday, October 17 from 9:30 am – 12:15 pm.

Building a Strong Management Team

Tuesday, October 16

9:30 AM – 10:45 AM

This panel discussion will answer such questions as, "How do you attract the talent needed to grow your business?" and "How does an early-stage company go about building a winning team?" This session will focus on workforce-related issues and executive compensation. The group will also talk about how to recruit and retain management talent, which is so crucial for start-up companies, and sometimes can make or break a great company.

Foreign Patent Filing Considerations & Strategies

Tuesday, October 16

11:00 AM – 12:15 PM

We all know protecting your intellectual property (IP) is important but sometimes we forget how important. This session will discuss how bioscience companies can protect their IP in foreign markets with different legal systems and requirements.

Partnering & Licensing

Tuesday, October 16

2:00 PM – 3:15 PM

Partnering & Licensing: Sounds relatively simple but identifying, developing and closing successful partnership agreements is an art. This session will cover the latest trends in identifying the right partner for your business, and offer advice when dealing with licensing, partnering and alliance management.

Reimbursement

Tuesday, October 16

3:30 PM – 4:45 PM

Join this afternoon session to learn how to use reimbursement strategies and considerations for a successful new product launch.

Important Patent Stuff No One Tells You

Tuesday, October 16

5:00 PM – 6:15 PM

This afternoon session will discuss patent terms and infringement. Part 1 is titled, "Coordination of Intellectual Property and Regulatory Filings" and Part 2 is titled, "Calculation of Patent Terms and Term Extensions"

Navigating the FDA

Wednesday, October 17

9:30 AM – 10:45 AM

The approval/clearance processes for devices, biologics and drugs are critical aspects in the commercialization process for biotech companies. Having a familiarity with the practical regulatory concerns and issues relating to the birth and launch of these product types is essential for biotech companies, patent and regulatory counsel as well as investment groups. However, these entities may not be sufficiently versed in the essentials of the approval process and the regulatory hurdles of the post-approval period. This panel will provide insights from industry experts in obtaining approval for biological, medical devices and pharmaceuticals and guidance as to the regulatory hurdles of the post-approval period including differing perspectives on safety.

From Seed to C: Raising Capital

Wednesday, October 17

11:00 AM – 12:15 PM

This session will discuss how to identify and raise the appropriate funds from angel investors and venture capital. Learn from the experts how to organize and prepare your company to attract capital from pre-seed to C-rounds. Gain insight into new and old strategies that work!

SCIENCE TRACK

Location: Key West

Science Track sessions will run all day Tuesday, October 16 from 9:30 am – 6:15 pm and on Wednesday, October 17 from 9:30 am – 12:15 pm.

Molecular Pathogenesis: Memoirs of a Disease?

Tuesday, October 16

9:30 AM – 10:45 AM

This session will focus on basic and clinical research related to the treatment and pathogenesis of underlying disease states. The study of mechanisms that give rise to a disease state, whether due to an exogenous agent or the body's own failure in maintaining the normal physiological checks and balances will be discussed. Understanding these essential pathways can provide a means for targeting a disease at crucial stages of its pathogenesis.

Biomarkers

Tuesday, October 16

11:00 AM – 12:15 PM

In the near future, biomarkers will be used to provide early predictions and diagnoses for a variety of treatable diseases if detected early enough. Personalized and predictive medicine is very close to reality. Biomarkers will also be used to decide which medications will be most likely to be therapeutic, which eliminates the guess work and experimentation.

Strategic Outsourcing

Tuesday, October 16

2:00 PM – 3:15 PM

How to utilize the services of a CRO to accelerate product development from clinical trial to marketplace. Panel will discuss establishing and negotiating CRO relationships and collaborating to meet development milestones.

Neurological Disorders

Tuesday, October 16

3:30 PM – 4:45 PM

Come learn about the exciting progress of the Miami Project for Spinal Cord Injury. Dr. Mary Bunge of UM Miller School of Medicine and the Miami Project will discuss the work done at the laboratory, which is focused on the following goals: (1) Protecting the spinal cord from secondary damage after the initial injury; and (2) Fostering regeneration of axons across and beyond the area of injury. This has been a long-time objective of Dr. Bunge's laboratory since moving to Miami in 1989. She will discuss the neuro-protective strategies that are being employed to reduce the amount of secondary tissue loss that involves interfering with the action of damaging cytokines and modifying the inflammatory response. Don't miss this informative update on her break-through recent developments.

Cardiovascular & Vascular Diseases

Tuesday, October 16

5:00 PM – 6:15 PM

You don't have to be a scientist to understand the impact and importance of the cutting-edge research and therapeutics being developed and commercialized in south Florida. Dr. Larry Lemanski, Dean of Biomedical Science at FAU will discuss his research in cardiomyopathy. Dr. Howard Leonhardt of BioHeart will discuss an innovative clinical therapy designed to populate regions of scar tissue within a patient's heart with living muscle tissue for the purpose of improving cardiac function. And Dr. Steven Lipschultz of the UM Miller School of Medicine will talk about his research in pediatric cardiomyopathy. This can't miss panel led by leading cardiac scientists will be an informative session highlighting Florida-based research and commercialization.

Cancer: An Ancient Nemesis in a Modern World

Wednesday, October 17

9:30 AM – 10:45 AM

Targeted cancer therapies are emerging as more specific and less toxic treatment approaches than current chemotherapy or radiation therapies. Development of such drugs, however, brings on several major challenges including how best to identify new drug targets from an understanding of the molecular changes underlying tumor cell survival and growth.

Stem Cell Research

Wednesday, October 17

11:00 AM – 12:15 PM

The potential applications for stem cells are only limited by our imagination. Since stem cells can differentiate into a wide variety of cells they're ideal candidates for repair of damaged tissue resulting from stroke, traumatic brain injury or a common heart attack. This session will focus on both how to obtain stem cells and how to use them to repair the damage done by a myocardial infarction.

RESOURCES TRACK

Location: Florida Ballroom C

Resource Track sessions will run all day Tuesday, October 16 from 9:30 am – 4:45 pm and on Wednesday, October 17 from 9:30 am – 12:15 pm.

What's in Your Petri Dish?

Tuesday, October 16

9:30 AM – 10:45 AM

Discover how your company can receive dollars to train your employees, find pools of highly skilled professionals, advertise open positions at no cost, and access state-of-the-art recruiting, interviewing and assessment tools.

NIH SBIR/STTR Programs: The Best Biotech (Non-Dilutive) VC Deal in Town

Tuesday, October 16

11:00 AM – 12:15 PM

Two important mechanisms by which the National Institutes of Health (NIH) helps bring new technologies to patients, clinicians and researchers are the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. With more than \$650 million reserved for small businesses and academic research partners, the NIH SBIR/STTR programs provide many early-stage life science companies with funding that is critical to the development and commercialization of novel technologies to prevent, diagnose and treat a range of diseases and disabilities. Learn from the NIH SBIR/STTR Program Manager about how your firm can tap this important funding resource. In addition, the National Cancer Institute will provide an overview of 16 new SBIR funding opportunities in areas such as anticancer agents, proteomics, nanotechnology and biomarkers.

Building Bridges: Connecting Community Colleges, Universities & Workforce

Tuesday, October 16

2:00 PM – 3:15 PM

Panel participants will highlight the community college and university bioscience training programs offered throughout the state based on varied industry needs (i.e., manufacturing, R&D, bioinformatics, engineering). Join this interactive panel to learn how these programs are building working relationships between departments and institutions to develop and promote interdisciplinary programs.

State Funding & Incentives

Tuesday, October 16

3:30 PM – 4:45 PM

Panel participants will discuss state funding mechanisms and tax incentives for attracting businesses, growth of your business and retention of your employees. How is Florida attracting new bioscience companies and institutes to the state, and what economic development tools and incentives are available to existing Florida businesses. And, finally, panelists will explain how bioscience companies can take full advantage of these incentives.

Redefining the Cluster: Florida Research Parks, Incubators & Facilities

Wednesday, October 17

9:30 AM – 10:45 AM

As Florida's bio industry grows, so does the need for incubator space, wet labs and manufacturing facilities. Learn about some of the available facilities in the state and what is planned for the future in Florida.

Florida Going Global

Wednesday, October 17

11:00 AM – 12:15 PM

This session will address the do's and don'ts of doing business internationally, emphasizing Florida's perspective. Topics will include sourcing international business opportunities, exporting, investing overseas, risk assessment and risk mitigation, patent and trademark protection. Speakers will offer views from the different components that are part of the international development process.

ROUNDTABLES

Location: President's Boardroom

These Roundtable sessions are designed to generate strategic discussions on key areas of concern that drive the industry in Medical Device, Real Estate & Facilities, Bio/Pharma, Education and Workforce, and Corporate Finance. **Please Note:** There is limited seating (20-30 participants only) and is limited for Bio-Florida members and prospects only.

Medical Device Executives Roundtable

Tuesday, October 16

9:30 AM – 10:45 AM

This roundtable will discuss issues specific to the medical device and technology and diagnostic markets. Seating is limited to senior medical device executives.

Real Estate & Facilities Roundtable

Tuesday, October 16

11:00 AM – 12:15 PM

Group participants will discuss issues specific to the design and development of bioscience facilities. Seating is limited to developers, architects, builders and other real estate professionals.

Bio/Pharma Executives Roundtable

Tuesday, October 16

2:00 PM – 3:15 PM

This group will talk about issues specific to the biotechnology, drug development and pharmaceutical markets. Seating is restricted to senior bio/pharma executives.

Education & Workforce Roundtable

Tuesday, October 16

3:30 PM – 4:45 PM

Don't Leave College Without It! Roundtable participants will learn how to grease the communication lines between what colleges and universities are teaching and what industry needs. A vital area in learning how to attract college graduations to your company and institution.

Corporate Finance Roundtable

Tuesday, October 16

5:00 PM – 6:15 PM

This roundtable will cover issues specific to the financial operation of bioscience companies. Seating is limited to senior corporate finance professionals.

CHRISTOPHER
&
WEISBERG, P.A.
ATTORNEYS AT LAW

If necessity is the
mother of invention,
we're the
overprotective father.®

Christopher & Weisberg is a law firm dedicated to intellectual property protection for a wide range of technologies, industries and services. We strive to help our worldwide clients develop, protect and exploit their intellectual property assets within the framework of their strategies, goals and budget. Our services include patents, trademarks, copyrights, litigation, arbitration, research and much more.

Intellectual Property Lawyers



For More Information, Call +1.800.978.2947.
www.cwiplaw.com

Miami-Fort Lauderdale | Washington, D.C.



ALEXANDRIA®

Keynote Host Sponsor

Alexandria Real Estate Equities, Inc. (ARE:NYSE), Landlord and Developer of Choice to the Life Science Industry, is the largest owner, cluster developer and pre-eminent first-in-class real estate investment trust focused principally on the ownership, operation, management, redevelopment, selective development and acquisition of properties containing office/laboratory space. Alexandria is the leading provider of real estate to the life science industry, and has an outstanding ten-year track record as a NYSE listed company with an approximate \$5.2 billion total market capitalization (as of March 31, 2007). Alexandria provides high-quality real estate, technical infrastructure, services and capital to the broad and diverse life science sector. Client tenants include institutional (universities and independent not-for-profit institutions), pharmaceutical, biotechnology, medical device, life science product, service, biodefense and translational medicine entities, as well as governmental agencies. Alexandria's international operating platform is based on the principle of "clustering," with assets and operations strategically located in key life science hub markets.

ALEXANDRIA REAL ESTATE EQUITIES, INC.

Corporate Headquarters

385 E. COLORADO BLVD.
SUITE 299
PASADENA, CA 91101

(626) 396-4828

Florida Operations

1555 PALM BEACH LAKES BLVD.
SUITE 1208
WEST PALM BEACH, FL 33401

(561) 683-5712
(561) 683-5717 (FAX)



Reception Host Sponsor

Phase 3 Properties, Inc. (P3P) is a commercial real estate Solutions Company focused on development, brokerage, and management. P3P has extensive experience in the life sciences, international border properties, student housing and traditional commercial assets. P3P is specifically dedicated to fostering the growth of the life science industry in emerging markets around the U.S and industrial parks in border towns. We pride ourselves on our ability to align the goals of both the public and private sectors seamlessly through complex projects. P3P's tightly knit team has been selectively recruited for their specific arenas of expertise from various sectors. Due to our nimble corporate structure, we are able to provide the creativity each project demands. From major research parks to individual industrial facilities, P3P develops class 'A' assets for our clients on an open book basis. This provides our tenants, clients, investors and partners the confidence that we will deliver the absolute best quality and economically efficient assets possible.

PHASE 3 PROPERTIES, INC.

Corporate Headquarters

8910 UNIVERSITY CENTER LANE
SUITE 265
SAN DIEGO, CA 92122


(858) 546-0888
(858) 546-0999 (FAX)
WWW.PHASE3PROPERTIES.COM

East Coast Office

2200 SOUTH DIXIE HWY.
SUITE 702-B
COCONUT GROVE, FL 33133

(858) 546-0888
(858) 546-0999 (FAX)

PLATINUM Sponsors



CONFERENCE BAG Sponsor



 **MARQUIS Sponsors**
.....



American Meetings, Inc.



WELCOME RECEPTION Sponsors
.....



PREMIER Sponsors 



UNIVERSITY OF CENTRAL FLORIDA
RESEARCH & COMMERCIALIZATION

 GOLD Sponsors



GOLD Sponsors





SILVER Sponsors



MEDIA Sponsors

THE ANGEL JOURNAL 

 **BioSpace**[®]
an onTargetjobs company

**BusinessWire**[®]
A Berkshire Hathaway Company

FierceBiotech
THE BIOTECH INDUSTRY'S DAILY MONITOR

Florida Trend
THE MAGAZINE OF FLORIDA BUSINESS

 **FSM**
fullspectrummedia

naturejobs
making science work

TechJournal
S O U T H

WOODPILE
STUDIOS


WOODPILESTUDIOS.COM

KEYNOTE Spotlight

By Christiana Lilly



G. Steven Burrill
CEO, Burrill & Company

IF THERE'S ANYONE THAT KNOWS ABOUT BIOSCIENCES, IT'S G. STEVEN BURRILL. HE STARTED HIS WORK IN THE FIELD OVER 40 YEARS AGO AND IS CONSIDERED ONE OF THE ORIGINAL PIONEERS OF BIOSCIENCES. IN 2002, SCIENTIFIC AMERICAN MAGAZINE NAMED HIM THE "BIOTECH INVESTMENT VISIONARY" IN THE MAGAZINE'S SCIENTIFIC AMERICAN 50 ISSUE. HERE, YOU HAVE THE OPPORTUNITY TO TAKE A SEAT WITH THE MAN WHO HAS BEEN THERE FROM THE BEGINNING.

What got you interested in biotechnology over 40 years ago?

It was clear to me back then that these companies had the potential to change the world and that we were harnessing the technology that man had not previously understood. There's a side of me that has a need to do good for mankind, and when you spend your time from when you get up in the morning to when you go to bed trying to cure AIDS, it's better than trying to make money on the Internet.

What were your hopes for the field at that time?

I think if you look broadly at biotechnology at that time, we knew it would have a dramatic impact on human health care. The reason for that wasn't that it had less impact on the other sides, but fundamentally the industry understood cancer better than it understood corn. Most of the capital was driven to health care outcomes so most of the technology was directed at health care. Now, we are more driven to the other sides of biotechnology and they're getting a lot more attention than they got before.

How do you view the growth of the industry?

I think it's been spectacular. If you go out 1,000 years from now and you write the history book, people will look up at this point in time and say that mankind's greatest achievement was understanding the molecular makeup of life. On the other hand, we've learned to cure lots of things on rats and mice and not to cure things on humans. There are thousands of diseases in the world that are not properly treated.

What are some points you are going to cover in your speech?

I'm going to talk a lot about the three P's: personalized, predictive and preventative health care. Also, a virtual integration and how the business models of building values have changed from 20 to 30 years ago. I'm going to try to put the industry in context so people can understand the pressures of what the health care dialogue in this country: what does Medicare mean

to the industry; how does government policy impact what is going on in the industry?

Where is biotechnology headed?

On the human health care side, personalized, predictive and preventative medicine and our ability to treat you at a level that can work for you, rather than the one size fits all. When we can get predictive, and we can begin to be preemptive and change that.

Where does Florida fit into all this?


We have an industry today where there are more companies outside of the U.S., so there are important things to recognize when you are trying to build an industry in Florida. When you look at the stage of Florida, one of the big questions is: do we have any reason in the state of Florida to think we can succeed? What does it take to be major industry players? I think there's an opportunity to both showcase what's happening in the world to Florida and show to the world what's happening in Florida. I think one of the differences in Florida as a stage is the things we can do that are going to be making a difference in the industry.

G. STEVEN BURRILL

IS GIVING THE LUNCHEON
KEYNOTE ADDRESS ON TUESDAY,
OCTOBER **16** AT **12:30** PM IN THE
GLOBAL BALLROOM

Burrill Life Sciences Media Group, a joint venture of Burrill & Company and Nielsen Business Media, produces world wide life sciences conferences, Biotech 2007, bio-intelligence reports, and The Journal of Life Sciences. Biotech 2007, our 21ST book on the “State of the Industry”, has been an important part of the biotech industry’s view of itself over the last 20 years.

Our Publications



Annual Report on the Biotech Industry



Biotech 2007—Life Sciences: A Global Transformation is the 21st Edition. The 500-page book offers a perspective on where the industry has been over the last 21 years and where it is headed.

The firm’s monthly and quarterly reports and publications provide a totally up-to-date resource for the latest insight, intelligence and information regarding the biotech industry.

They include:

- The Burrill Canadian Biotech News Monthly
- The Burrill Greater China Life Sciences Quarterly
- The Burrill Japan Life Sciences Quarterly
- The Burrill India Life Sciences Quarterly
- The Burrill European Life Sciences Quarterly
- The Burrill M&A/Partnering Quarterly
- The Burrill Personalized Medicine Report
- The Burrill Stem Cell Report
- The Journal of Life Sciences

Our Industry Events



- The Stem Cell Meeting (March)
- The India Life Sciences Partnering Meeting (May)
- The China Life Sciences Partnering Meeting (May)
- The Japan Biotech Meeting (September)
- The World Stem Cell Policy and Advocacy Summit (October)
- The Biotech Meeting at Laguna Niguel (October)
- The Indiana Life Sciences Forum (October)
- The Burrill Personalized Medicine Meeting (November)
- The Burrill Health and Wellness Meeting (TBD)

To order Biotech 2007, subscribe to any of the Burrill & Company publications, or obtain registration details on our events, visit www.burrillandco.com, call 415-591-5400 or email: publications@b-c.com or events@b-c.com

aug07

Medical City Moving Ahead

THE UNIVERSITY OF CENTRAL FLORIDA's Health Sciences campus at Lake Nona is bustling. Buildings are going up, laboratories are going in and the potential economic impact for the state of Florida continues to rise. UCF's list of partners now includes The Burnham Institute, Florida Hospital and Orlando Regional Healthcare, Nemours, the Scripps Research Institute and the University of Florida. With the addition of the Burnett School of Biomedical Sciences, UCF's College of Medicine now has a bank of researchers studying treatments for cardiovascular disease, cancer and neurodegenerative diseases such as Alzheimer's.

UCF stands for opportunity. Working together to win together. The rise of the Medical City at Lake Nona is enabling life-changing discoveries, for Floridians and the world.

www.research.ucf.edu

SOME RECENT FINDINGS BY UCF RESEARCHERS

A way to control the protein that prevents stem cells from replicating healthy neurons in Alzheimer's disease patients. (Dr. Kiminobu Sugaya)

A link between DNA repair and gene silencing that may explain why tumor suppressor genes (genes that prevent cell division) are frequently shut off in cancer cells. (Dr. Mark Muller)

A technique for genetically engineering tobacco plants with the insulin gene and successfully treating diabetic mice (Dr. Henry Daniell)

The role of a newly discovered gene in treating heart disease at the molecular level (Dr. Pappachan Kolattukudy)

UCF  Stands For Opportunity



POLICY ISSUES **Pharma, Biotech & Device**

THERE ARE MANY LEGISLATIVE ISSUES SURROUNDING THE BIOSCIENCE INDUSTRY. AT THIS YEAR'S CONFERENCE, ATTENDEES HAVE THE OPPORTUNITY TO LEARN MORE ABOUT VARIOUS TOPICS TO TAKE BACK WITH THEM TO THE WORKFORCE AND CONTRIBUTE THEIR VOICE IN TALLAHASSEE AND WASHINGTON. HERE, WE HAVE SUPPLIED YOU WITH IMPORTANT GOVERNMENT AFFAIRS RESOURCES LINKS TO FURTHER EDUCATE YOURSELF ON THE GOVERNMENT'S ROLE IN BIOSCIENCE.

Universal Coverage

www.advamed.org

AdvaMed's Board of Directors recently approved a sweeping health care reform plan that would provide every American with the opportunity to purchase affordable insurance meeting a federal standard of coverage.

www.bio.org

The Biotechnology Industry Organization urged the Connector Board to include a prescription drug benefit as part of the standards for minimum creditable coverage.

www.phrma.org

PhRMA commends Health Care Coverage for the Uninsured (HCCU) for addressing the important and serious problem of improving access to health coverage. While we are still reviewing their plan, this much is clear: without access to such coverage, American families face a tremendous financial burden and too often go without the care and medicines they need.

Economic Development Best Practices

www.bio.org/local/industrydev/

Ten years ago, the competition for the bioscience industry was primarily within U.S. borders. However, a variety of factors - low cost labor, speed of information dissemination and available risk capital - have increased global competition for the industry.

www.bio.org/local/battelle2006/

State Bioscience Initiatives 2006 presents updated data, examines growth trends and identifies metropolitan areas with the largest and most concentrated employment in each of the bioscience subsectors identified in the 2004 report. These include agricultural feedstock and chemicals, drugs and pharmaceuticals, medical devices and equipment, and research, testing and medical laboratories.

www.bio.org/local/battelle2007/

Bioscience is a knowledge-based industry and requires a region to harness its best in terms of talent and leveraging niche characteristics in order to effectively grow business and boost employment. The industry cluster is unique in that it requires a strong foundation and significant investments in scientific research and development.

Patent Reform

www.bio.org/news

Appearing on behalf of BIO, Alkermes, Inc., Senior Vice President and General Counsel Kathryn Biberstein outlined the organization's view on patent reforms and its specific concerns with S. 1145 in testimony delivered before a hearing held by the Judiciary Committee of the United States Senate.

www.bio.org/ip/domestic/

BIO welcomes efforts by Congress - particularly House Judiciary Committee Chairman John Conyers (D-MI), Ranking Member Lamar Smith (R-TX), Intellectual Property Subcommittee Chair Howard Berman (D-CA) and Subcommittee Ranking Member Howard Coble (R-NC) - to make improvements to the U.S. patent system. Done correctly, patent reform will help provide the necessary incentives that drive continued development of biomedical and other biotechnology innovations.

www.phrma.org

Pharmaceutical companies rely on government-granted patents to protect their huge investments in researching and developing new drugs. Without patents to protect all the inventions necessary to develop a drug for a limited time, others could simply copy the drugs immediately, offering their versions at a reduced price, since they did not incur the high costs to develop the drug.

Follow-On Biologics

www.bio.org/healthcare/followonbkg/

In order to ensure that new pioneer biotechnology products continue to reach patients and physicians, any statutory pathway for the approval of follow-on biologics must protect patient safety and preserve incentives to innovate.

www.phrma.org/news_room/press_releases

PhRMA stands ready to support the establishment of a regulatory pathway for follow-on biologics if patient safety can be assured and the innovation of future medicines is not compromised. However, we remain concerned that patient safety could be at significant risk if the current legislative follow-on biologics proposals move forward.

PDUFA / FDARA / FDAAA

www.bio.org/healthcare/pdufa/

The Prescription Drug User Fee Act (PDUFA), first enacted in 1992 and revised in 1997 and 2002, is a program under which the pharmaceutical/biotechnology industry pays certain “user fees” to the Food and Drug Administration (FDA).

www.phrma.org/issues/

Disease is our common enemy. America’s research-based pharmaceutical companies are global leaders in creating new cures and treatments to help patients fight disease.

A SNEAK PEEK INTO THE LEGISLATIVE PLENARY SESSION -- PLEASE JOIN US FOR THIS INFORMATIVE DISCUSSION ON WEDNESDAY, OCTOBER 17 AT 8:30 TO 9:15 AM.

UNIVERSAL COVERAGE

Do the pharmaceutical, biotech and medical device industries have a position on universal coverage and coverage for the un- and under-insured?

ECONOMIC DEVELOPMENT BEST PRACTICES

40 states and an array of countries list biotech as a “target industry.” Florida has recently invested hundreds of millions of dollars in Scripps, Torrey Pines, Burnham, the Centers of Excellence, the Florida Opportunity Fund and several other initiatives. How does Florida stack up against other states? What are the hurdles in competing with California, Massachusetts and North Carolina?

The Massachusetts Economic Development Authority and the Mass Biotech Council have worked together to develop “shovel ready sites” for the purpose of facilitating biotech siting in Massachusetts, paying off with the recent announcement by Bristol Myers Squibb of the location of a facility at the former Ft. Devens to employ 550 people. What land use laws and policies matter most in facility siting decisions? And how can policy-makers smooth the way for industry to place facilities in Florida?

New Jersey creates an economic incentive for start up and innovator companies by allowing companies to sell or trade their Net Operating Losses and Research and Development Tax Credits. Is this a trend that other states are employing? How would these and similar financing tactics impact Florida's bioscience industry?

PATENT REFORM

What is at stake for biotech in the patent reform battle? What is the likelihood of passage of patent reform during

this Congress? Under most circumstances, the IT and biotech industries are on the same political page? Why opposed on this issue?

FOLLOW-ON BIOLOGICS (FOB)

What is the status of FOB legislation? Will innovators be adequately protected? Will competitors be required to conduct clinical trials? If a pathway for FOBs becomes available, how will it impact the biological and pharmaceutical industries overall?

PDUFA / FDARA / FDAAA

The Congress recently passed the FDA Amendments Act of 2007” (FDAAA, formerly FDARA) (H.R. 3580) how will those changes impact the industry?

Biographies



Brian Agnew
Assistant Director for Economic & Policy Research
Pfizer

At Pfizer since 2002, Brian Agnew is Assistant Director for Economic Policy & Research, overseeing academic research on topics such as the impact of pharmaceutical access restrictions on physicians and patients. He also regularly conducts

financial impact analyses of policy developments affecting the pharmaceutical industry, including the new Medicare Part D prescription drug benefit. Prior to joining Pfizer, he was a Health Insurance Specialist with the Centers for Medicare and Medicaid Services, where he was responsible for writing regulations including ones that established new sanctions for nursing homes and clinical laboratories and quality assurance requirements for Medicare managed care plans. He received his BA from Dartmouth College and his MBA from the Yale School of Management.



Russel Allinson, RPh, MS
Principal
Therigy

Russ Allinson is a seasoned leader with over 25 years of progressive managerial experience in many areas of pharmacy and healthcare operations.

Allinson received his BS in Pharmacy degree from the University of Pittsburgh and his MS

in Pharmacy Administration from The Ohio State University. He completed an administrative/clinical residency at Riverside Methodist Hospital. In addition, he has completed many executive courses in Quality Management, Finance, Purchasing and Inventory Control.

During his career, Mr. Allinson has worked in both line and staff roles in several different areas including hospital pharmacy, hospital administration, and specialty pharmacy. He has had the opportunity to work with many different disciplines and apply his management and leadership skills to effect change and improve performance. Mr. Allinson has held numerous senior management positions including Corporate Director of Quality, Vice President of Hospital Administration, Vice President and Senior Vice President of Pharmacy Operations, Senior VP/Chief Pharmacist, and General Manager.

While his business responsibilities have been demanding, he has found time to support his community and his profession. He taught several modules of the introductory pharmacy course at the University of Pittsburgh School of Pharmacy and was a volunteer leader for the Annual Pharmacy Student Leadership Retreat for several years. He received the Alumni of the Year award from the University of Pittsburgh School of Pharmacy in 1996. He enjoys public speaking and has been an invited speaker at numerous national healthcare programs.

Gary A. Ascani
President & CEO
Banyan Biomarkers



Gary A. Ascani is President and CEO of Banyan Biomarkers, an early-stage, in-vitro diagnostics company developing protein biomarker point-of-care products for the detection and monitoring of traumatic brain injury. Mr.

Ascani has over 30 years' experience in the biotechnology/medical products industry. Mr. Ascani has held management and executive positions with Hyland Labs, a Division of Baxter-Travenol, Chicago, IL; Monoclonal Antibodies, Inc., a biotechnology company located in Mt. View, CA; Molecular Analysis, Inc., a biotechnology start-up in Houston, TX; T Cell Diagnostics, a biotechnology start-up in Cambridge, MA; and Diamedix, Inc., a division of Ivax Corp. Miami, FL. In 1999, Mr. Ascani co-founded Vulcan Medical Ventures, Inc. (VMV) of Birmingham, AL, a small venture capital firm focused on seed stage venture financing. In 2001, VMV closed a Series A Preferred Stock Financing for PNP Therapeutics, Inc. (PNP), an early-stage biopharmaceutical company developing platform technology and proprietary products for the treatment of cancer. It was at that time that Mr. Ascani became the company's Chairman and CEO. Mr. Ascani continues to serve as an advisor to PNP's Board of Directors. Prior to relocating to Gainesville, Mr. Ascani served as a member of the Board of Directors of Birmingham Venture Club, a member of the Executive Committee of the Board of Directors and Treasurer of Biotechnology Association of Alabama, and was honored by the Birmingham Business Journal with his selection to the first annual "Who's Who in Health Care."

In today's idea- and brand-driven economy,
intellectual property is a company's most valuable asset.

Patent Pending

Akerman Senterfitt's Intellectual Property Practice is the largest and most broadly experienced in Florida. With a national presence, we represent clients in more than 35 countries, as well as many international companies doing business in the United States. A majority of our intellectual property attorneys are engineers and scientists offering our clients their knowledge and extensive experience in obtaining broader patents, strengthening and protecting brands, drafting and negotiating the highest quality agreements, developing more profitable licenses, and litigating more effectively.

Akerman Senterfitt
ATTORNEYS AT LAW

www.akerman.com

FT. LAUDERDALE ■ JACKSONVILLE ■ LOS ANGELES ■ MADISON ■ MIAMI ■ ORLANDO ■ NEW YORK
TALLAHASSEE ■ TAMPA ■ TYSONS CORNER ■ WASHINGTON, D.C. ■ WEST PALM BEACH



Christopher J. Badgley
Vice President of State
Government Affairs
Pharmaceutical Research and
Manufacturers of America
(PhRMA)

Vice President for State Government Affairs, for the Pharmaceutical Research and Manufacturers of America (PhRMA). Joining PhRMA in October 1999,

Mr. Badgley oversees the daily management of two Deputy Vice-Presidents, and eight Regional Directors, in addition to contract lobbyists in each state. Additionally, the Associate Vice-President for Minority Relations reports to Mr. Badgley.

Mr. Badgley joined PhRMA after an extensive career at Wyeth Pharmaceuticals (formerly Wyeth-Ayerst Pharmaceuticals) beginning in 1981, after coming to the pharmaceutical industry from the insurance industry. During this time, he occupied various sales, marketing and government relations positions in the company including: Territory Sales Representative, Tactical Sales Representative, National Field Trainer, District Sales Manager, Manager of Marketing Programs - Trade and State Government Relations, and Director, State Government Relations. In May 1997, Mr. Badgley was promoted to Senior Director, State Government Affairs, overseeing the successful merger and integration of the American Home Products Corporation State Government Affairs group into the Wyeth-Ayerst program.

Mr. Badgley was a Steering Committee member of the Healthcare Institute of New Jersey (HINJ), a past Board member of the Texas Healthcare and Bioscience Institute (THBI), a member of the Associates Advisory Committee of the Council of State Government (CSG), and a member of various health and human services committees for CSG, the American Legislative Exchange Council (ALEC), and the National Conference of State Legislatures (NCSL). He also served on the state government relations committees of the Biotechnology Industry Organization (BIO), Health Industry Manufacturers Association (HIMA, now AviMed), and Consumer Healthcare Products Association (CHPA).

Christopher J. Badgley, a New Jersey native, is a Bachelor of Science graduate from the University of Wisconsin - Stevens Point, majoring in Wildlife Management and Fisheries Biology, with a minor in Biology.

Mr. Badgley is an avid golfer, flyfisherman and blues guitar player. He lives in the Washington area with his wife Barbara and daughter Clare.

Renée A. Benton
President & CEO
Tampa Bay WorkForce Alliance



Renée A. Benton, president and chief executive officer, provides leadership to Tampa Bay WorkForce Alliance, Inc. (TBWA), which provides essential workforce services to the Tampa Bay business community. Over the past three years, she has led the organization's transition to a business delivery model, earning distinction from the business community and recognition by TBWA associates. In 2004, Tampa Bay WorkForce Alliance was named finalist for Business of the Year by the Tampa Bay Business Journal. Ms. Benton's involvement extends to participation as board director of the Greater Tampa Chamber of Commerce and member of its prominent Committee of 100, the economic development arm of the GTCC.

Prior to joining Tampa Bay WorkForce Alliance, Ms. Benton was based in Tallahassee, Florida where she served as interim director of the Office of Legislative and Public Affairs for the Department of Labor.

Ms. Benton is a nationally recognized expert in the area of workforce development and has received accolades for the development of an early model of innovative employment services. In addition, Ms. Benton has been cited by the Office of the President of the United States for innovative government leadership. She has received multiple commendations.

Ms. Benton is a graduate of Florida A & M University, where she received a Bachelor of Science degree. She also holds a Master of Business Administration from Atlanta University.

Heather J. Belmont,
PhD
Chairperson, Biology/Health &
Wellness
Miami Dade College



Heather J. Belmont, PhD, serves as the Chairperson of the Biology/Health & Wellness Department at Miami Dade College - North Campus. In addition to managing the day-to-day operations of the department, Dr. Belmont oversees several workforce-related grants totaling over 3.0 million dollars in external funding. Dr. Belmont has also served as the Director of MDC's Biotechnology Program where she was instrumental in program design and implementation. Prior to joining the Miami Dade College family, Dr. Belmont worked for two biotechnology companies, Sunol Molecular and Altor Bioscience, where she conducted research on therapeutic anti-viral and anti-cancer biologics.

SALIWANCHIK, LLOYD & SALIWANCHIK

INTELLECTUAL PROPERTY LAW

PERSONAL TOUCH GLOBAL IMPACT™

BIOTECHNOLOGY

PHARMACEUTICALS

MEDICAL DEVICES



ORGANIC CHEMISTRY

MATERIALS SCIENCE

ELECTRONICS

OPTICS

MECHANICAL ENGINEERING



WWW.SLSPATENTS.COM

3107 S.W. Williston Road ■ Gainesville, Florida 32608 ■ PH: (352) 375-8100 ■ Fax: (352) 372-5800

She has co-authored multiple peer-reviewed journal articles and two patent applications. Dr. Belmont holds a Bachelor of Arts degree from Ithaca College and a Doctor of Philosophy degree from the University of Miami.



David M. Binninger
Associate Professor
Florida Atlantic University

In his career, Binninger has traveled around the world to speak. He was selected to participate in the 2006 National Academies Summer Institute on Undergraduate Education in Biology in Madison, WI from June 25-30, 2006, which was supported in part by the Howard Hughes Medical

Institute. Binninger was invited to a plenary lecture "Biological Effects of Extremely Low Frequency (ELF) Magnetic Fields: A Molecular Analysis at the First Bio-Systems Symposium and Workshop" held at Prince of Songkri University in Hat Yi, Thailand from July 24-29, 1999. He also spoke in a lecture entitled, "Normal Cell Biology and Probable Sites Of Interaction With Extremely Low Frequency EMF" at The 20th Annual International Meeting of the Bioelectromagnetics Society in June 1998. In 1997, he went to Tokushima University, University of Tokyo Medical School and The Sikoko Research Institute for a research lecture. He was also invited

to a symposium lecture, "Use of non-mammalian systems to investigate mechanism mediating biological interactions with electromagnetic fields" at The Second World Congress for Electricity and Magnetism in Biology and Medicine that was held in Bologna, Italy from June 8-13, 1997.

Warner Bonner
Principal
Phase 3 Properties, Inc.

Warner Bonner, Principal of Phase 3 Properties, Inc. (P3P) is dedicated to fostering the growth of the life science industry in emerging markets around the U.S. Phase 3 prides itself on their ability to align the goals of both the public and private sectors seamlessly in through complex projects. After 5 years with CB Richard Ellis' Life Sciences Group, Warner joined Phase 3 in 2000 during the company's first year of inception. Warner is strictly focused on large-scale public/private projects on behalf of universities, health care providers, research institutions and local municipalities. Most notably, he is a key development partner in a number of projects that range from the master development of a 640-acre international U.S. commercial border crossing to the development of major life science research centers. Two of the main life science research centers currently under development include: The \$350 million Asia



We Build Biotech.



TORREY PINES
TUFTS UNIVERSITY
SUNY BUFFALO
UNIVERSITY OF NEW HAMPSHIRE
JACKSON LABORATORIES
BOWDOIN COLLEGE
U-MASS DARTMOUTH
HARVARD UNIVERSITY
MIT

Suffolk Construction is honored to be building what will be the first completed Biotech Facility in South Florida.

Call to find out how you can build with our experience.

SUFFOLK
(561) 832-1616

CGC 047581 CGC 059578

NINTH ANNUAL Southeastern BIO Investor Forum

The premiere regional life sciences venture capital conference

NOVEMBER 7-8, 2007
PINEHURST, NORTH CAROLINA



Learn about the best life sciences venture opportunities in Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, Virginia, and beyond.

To find out more, visit
www.sebio.org/investorforum/2007

SEBIO
Investor Forum

SOUTHEAST
BIO-PLAN
COMPETITION

Winner of the 1st Annual
BIO/Plan competition
will be announced

Pacific Research Center, which is in collaboration with the State of Hawaii and the Royal Bishop Estates of Hawaii, and most recently the \$300 million New York Science Center, which is in collaboration with the city and state of New York. Collectively with local principal, Tom Lewis, Warner and the Phase 3 team are actively pursuing biotech development efforts in the Florida market.



Patti Breedlove
Assistant Director
Sid Martin Biotechnology
Incubator
University of Florida

Assistant Director of the University of Florida's nationally recognized Sid Martin Biotechnology Incubator. She has an MS in Health Science from the University of Utah and spent 25 years founding, working in, and

running community health organizations in California, Utah, Oregon and New Jersey.



Mary Bartlett Bunge, PhD
Professor, Cell Biology
& Anatomy
University of Miami

Bunge is Professor of Cell Biology and Anatomy and Neurological Surgery, and the Christine E. Lynn Distinguished Professor of Neuroscience at the University of Miami

Leonard M. Miller School of Medicine, working in The Miami Project to Cure Paralysis. Dr. Bunge was a pioneer in elucidating the structure and function of cells that support nerve fibers and, more recently, in developing a new spinal cord injury model and novel combination strategies to improve repair of the injured spinal cord. Her laboratory currently conducts preclinical studies aimed at developing neuroprotective or neuroregenerative therapies for spinal cord injuries. These therapies include the transplantation of genetically modified cells to facilitate regeneration in seriously damaged spinal cords. These cells are placed into the injury site within polymer conduits. She has served on NIH study sections and the National Advisory NINDS council. She has received the Wakeman Award (1996) for her seminal contributions to the field of spinal cord injury repair, the Christopher Reeve Research Medal for Spinal Cord Repair (2001), the Javits Neuroscience Investigator Award (1998), The Lois Pope LIFE International Research Award (2005) and was the first recipient of the Mika Salpeter Women in Neuroscience Lifetime Achievement Award (2000). From 1996-97 she served as Interim Scientific Director of The Miami Project to Cure Paralysis. She was recently honored by her alma mater, Simmons College, with an honorary Doctor of Humane Science degree. She currently

is a member of the International Research Consortium of the Christopher and Dana Reeve Foundation and the Dana Alliance for Brain initiatives.

Paul Burgess
Patent Attorney
Johnson & Johnson

Paul Burgess has been a patent attorney for Johnson & Johnson since 2005. He represents a variety of Johnson & Johnson pharmaceutical companies covering product and technology areas such as drug delivery, small molecule chemistry and biotechnology. Prior to joining Johnson & Johnson, Burgess was a patent attorney for Transform Pharmaceuticals. Burgess has also worked as a scientist in the immunology group of Genetics Institute. He received his juris doctor from Northeastern University School of Law, his master's in Biochemical/Biomedical Science from Northeastern University, and his bachelor's in Biology from Merrimack College.

G. Steven Burrill
CEO
Burrill & Company



G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Board of Pharmasset (NASDAQ: VRUS) and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (NASDAQ: DEPO), Intranasal, Phytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50).

Mr. Burrill is a founder and currently serves as the Chairman of the Board of the Foundation for the National Medals of Science and Technology. Additionally, he serves as Chairman of the Board on Campaign for Medical Research as well as Chairman of the San Francisco Mayor's Biotech Advisory Committee (MAYBAC). Other not-for-profit activities include serving on the Boards of Directors for the Bay Area Science Infrastructure Consortium, BayBio, California Healthcare Institute, The Exploratorium, Genetics Policy Institute, The Kellogg Center for Biotechnology, Kramden Institute, The National Health Museum, and Research!America. He also serves as an advisor on the MIT Center for Biomedical Innovation.



Eugenio A. Cefali, PhD
CEO
Eos Lifesciences

Eugenio A. Cefali, PharmD, PhD brings with him 20 years of drug development experience including formulation development and evaluation, new chemical entity development, pharmacokinetics, bioavailability and clinical develop-

ment. Prior to arriving at Eos, Gene contributed significantly to the success of Kos Pharmaceuticals where he held several leadership positions during his tenure including heading Kos' virtual HDL and Apo A lipoprotein drug discovery initiative. At Kos, Gene quickly became an expert in niacin pharmacokinetics and bioavailability resulting in several patents for Kos' flagship products; Niaspan, Advicor and Simcor. Prior to Kos, Gene was integral in the early development of a dopamine agonist for use in Parkinson's Disease. Gene received a BS in Pharmacy at St. John's University and both a PharmD and PhD in pharmacokinetics and pharmaceuticals from Virginia Commonwealth University.



Srikumar P. Chellappan, PhD
Professor, Drug Discovery Program
H. Lee Moffitt Cancer Center and Research Institute

Srikumar Chellappan received his PhD in Biochemistry from the Indian Institute of Science, Bangalore, India, and did his post-doctoral training at the

Duke University Medical Center, Durham, North Carolina. He was an Assistant Professor at the College of Physicians and Surgeons, Columbia University, New York, from 1992 to 2001.

Dr. Chellappan joined the Department of Interdisciplinary Oncology at USF and the Drug Discovery Program at the H. Lee Moffitt Cancer Center as an Associate Professor in 2001; he currently holds the rank of Professor. He has authored more than fifty scientific publications and was named the Moffitt Cancer Center Research Scientist of the Year for 2007.

Dr. Chellappan has served on various NIH study sections and site visit teams and is currently a charter member of the Tumor Progression and Metastasis study section. His work focuses on understanding the molecular mechanisms regulating cell proliferation and how these regulatory pathways are altered in cancer. His laboratory is currently developing novel anti-cancer drugs that target aberrant signaling cascades operating in cancer cells.

John Christopher
Partner
Christopher & Weisberg

John Christopher is a partner in the Miami-Fort Lauderdale office of Christopher & Weisberg. He is a registered patent attorney and his practice encompasses all aspects of patent, trademark and copyright portfolio development, management, exploitation and enforcement, as well as business transactions related to intellectual property. He has almost 20 years of experience representing medical device and biotechnology companies. Christopher was awarded a juris doctor from the Northeastern University School of Law and a bachelor's degree from the United States Air Force Academy. He is licensed to practice law in Florida and Massachusetts. An active member of the American Intellectual Property Law Association (AIPLA) for many years, he has served as an association delegate to Asia, meeting with and making presentations to senior legal and government officials in Hong Kong, China and South Korea. Christopher is also a member of the International Trademark Association (INTA), the Broward County Bar Association where he serves as chairman of the Business Law Section, and the Intellectual Property Law Association of Florida. Christopher has been recognized by South Florida CEO Magazine as one of the top lawyers in South Florida.

Mimi Coenen
Business Service Director
Workforce Alliance in Palm Beach County

Mimi Coenen manages a team of 15 Business Service Consultants addressing placement and training needs for regional employers. Prior to this Ms. Coenen worked with Workforce One in Ft. Lauderdale, FL where she administered grants and promoted services among Broward County employers. For the ten years prior to that, Mimi owned and operated an auto repair/truck rental dealership, where she grew the rental business to become the largest in the Southeast Region. She sold this business and began her successful journey into the workforce industry.

David L. Day
Director Office of Technology Licensing
Director, Sid Martin Biotechnology Incubator
University of Florida

Day joined the Office of Technology Licensing at the University of Florida on April 2, 2001, where he oversees the commercialization efforts of all UF technologies. Mr. Day has served as director of the Sid Martin Biotechnology Incubator in Alachua, FL since 2003. Mr. Day



GROWING PFIZER PRESENCE IN BIOLOGICS

Biologics medicines, like Sutent and Exubera, generated about \$1.5 billion in 2006 and the company expects revenues from those and other new biologics will **triple** by 2010. Pfizer, the world's largest privately-funded biomedical research organization, has grown its biologics from **one** to **36** projects over the past decade and within the last year, has entered into about **100** strategic alliances with biotech companies around the world.



serves on the Board of Directors of BioFlorida, the McKnight Brain Institute Advisory Panel, the Board of Directors Executive Committee of the Florida Research Consortium, and the board of Directors Executive Committee of the Southeastern Bio Investors Forum.

From 1995 to 2001, he served as the Director of the UAB Research Foundation at the University of Alabama at Birmingham. David received a Master of Business Administration from the University of Alabama in 1987 and has a Masters of Library and Information Studies from the University of Alabama, 1977.



Carolyn Donaldson
Vice President, Human Resources
Noven Pharmaceuticals

Longtime Miami resident, Carolyn Donaldson is a familiar figure in Florida's executive, university, church and volunteer communities. Her distinguished history of service in the public and private sectors gives her a unique ability to forge partnerships with

education, government, business and to positively influence the goals, aspirations and morals of young women in South Florida.

As Vice President of Human Resources for Miami-based Noven Pharmaceuticals (Nasdaq: NOVN), a leading developer of transdermal and transmucosal drug delivery technologies and products, Ms. Donaldson plays a pivotal role as a member of the executive team that collaborates to build the organizational infrastructure, management effectiveness and professional strength required to sustain the company's growth and profitability. She previously served in a similar capacity for Miami-based IVAX Corporation (AMEX: IVX), a world leader in generic pharmaceuticals. She also served Cordis Corporation for over thirteen years, where she received the prestigious Founder's Award in 1994 for her outstanding contributions to the organization and community. Her hard work, talent and professionalism earned her and Cordis the PALM award for innovation and excellence in the area of Human Resource Management and Development. In March 2004, she was recognized for superior, long term accomplishments and consistent excellence and dedication in Human Resources Management, when she was honored by the Greater Miami Society of Human Resources (GMSHRM) as the recipient of the Life Time Achievement Award. Her contributions to the Human Resources profession were acknowledged again in August, 2005 when she was named an honoree by the South Florida Business Journal for Excellence in Human Resources.

Carolyn's professional and community contributions have been acknowledged statewide as, in 1995, the Florida Senate confirmed her position on the Enterprise Florida Board of Directors Jobs and Education Partnership. In addition, the late Florida Governor Lawton Chiles appointed Ms. Donaldson to

the State Occupation Information Coordinating Committee. She has in addition served on the Visiting Committee of the University of Miami School of Continuing Studies, as Committee Chairperson for the Florida Department of Commerce Quick Response (Senate Bill 2382), and as a member of the Board of Directors and Executive Committee of the South Florida Manufacturers Association.

Ms. Donaldson has been a tireless advocate and supporter of the United Way of Miami Dade County for the past 27 years. She has served as a trustee since 1994 and is currently on the Board of Directors and Co-Chair for the Community Investment Committee.

She continues to serve as an active member on several community based Boards serving most recently as a member of the Board of Governors for the Greater Miami Chamber of Commerce and as Co-Chair of the Internship Opportunities Committee a branch of the Education and Training Committee. Having worked in the pharmaceutical, biopharmaceutical and medical device industries for the past 25+ years, Carolyn is committed to raising the level of awareness of opportunities in these industries. Her focus is to ensure that, as the industry focus shifts and the prevalence of opportunities increases, women and minorities are not left behind in the areas of science, engineering and biomedical technology.

Her advanced degree studies include a scheduled completion in August, 2006 of a Master's Degree in Human Resources Management from Florida International University, coursework at the University of Miami Executive MBA Program, Florida International University (BS in Business Management) and Miami Dade Community College. Subsequent training and credentials include studies at UCLA Executive Development Program, the Center for Creative Leadership, Dale Carnegie and the National Accreditation Institute for HRD. She is also a graduate of two Miami community-based development programs: Project Blueprint and Leadership Miami.

William M. Egan, PhD
Executive Director
PharmaNet Consulting

In January, 2005, Dr. Egan joined PharmaNet Consulting as Executive Director, serving as a consultant in biological products, primarily vaccines, allergenics, and therapeutic proteins. Prior to joining PharmaNet, Dr. Egan spent 28 years at FDA. Dr. Egan was Deputy Director for FDA's Office of Vaccines Research and Review (OVRR) from 1995 through 2005 and its Associate Director for Research between 1993 and 2005. From June, 2003 until his retirement in January, 2005 (as well as previously from 1999 through 2001), Dr. Egan served as Acting Director for OVRR. As Director and Deputy Director, Dr. Egan had oversight responsibility for the vaccine regulatory process



FLORIDA. A RISING STAR IN LIFE SCIENCES.



Biotechnology

The energy generated by Florida's biotechnology sector is palpable. Since the arrival of The Scripps Research Institute in 2004, the state has attracted other world-class biotechnology research organizations such as the Burnham Institute for Medical Research, and Torrey Pines Institute for Molecular Studies and many renowned scientists and researchers.

Size: Approximately 100 companies

Areas of Excellence:

Bioinformatics, Marine Biotech, Biopharmaceuticals.

Fact: Florida's state universities generated over 130 patents and founded 20 life sciences spin-offs in 2004-2005.

Pharmaceuticals


Florida companies are involved in all aspects of the pharmaceutical industry and invest heavily in research and development (R&D).

Size: Approximately 90 companies


Areas of Excellence: Treatments for cardiovascular and respiratory diseases, Generics, Nutraceuticals, Over-the-counter drug manufacturing.

Fact: Nanotherapeutics, Inc., was recently recognized for its innovative method of using nano-scale particle delivery to improve the safety and effectiveness of drugs.

FLORIDA'S LIFE SCIENCES WORKFORCE



Source: Occupational Employment Statistics, 2004



Florida's Biotech/Pharma Companies

- Biotechnology
- Pharmaceutical

BIO 2008

June 17-20
San Diego, CA

Contact us for
partnership opportunities

Thanks to innovative companies like yours, Florida's Biotech and Pharma cluster is growing by leaps and bounds.

If you are looking to expand your business, contact Enterprise Florida (EFI)-the Statewide Economic Development Organization-for assistance.

For additional information about Florida's Business Advantages, contact:

Brenda Workman - Enterprise Florida
Director, Business Retention & Life Sciences
407-956-5607 | bworkman@eflorida.com

The University of Florida transfers its research into products that benefit everyone.



We help transfer research created by our faculty into companies that create jobs and save lives.
Visit our websites to find out more.

TECH LICENSING

www.rgp.ufl.edu/otl

DRUG DEVELOPMENT

<http://cerhb.rgp.ufl.edu>

BIO-BUSINESS INCUBATION

www.biotech.ufl.org

The University of Florida ranks No. 1 among public universities in the U.S. and Canada in moving technology to the marketplace, according to a newly released study by the Milken Institute. Over half-billion dollars of research annually, combined with aggressive technology transfer efforts, and state of the art resources such as the nationally-ranked Sid Martin Biotechnology Incubator and a new biopharmaceutical manufacturing facility, Florida BioLogix, makes UF a leader at commercializing technologies to cure diseases and improve lives.

UF | UNIVERSITY of
FLORIDA

in the United States; he also represented OVRP to Congress, various national and international groups and agencies, including the World Health Organization and various National Control Agencies. As Associate Director for Research, Dr. Egan was responsible for setting directions and overseeing the research programs within OVRP.


Dr. Egan's research experience within FDA includes 13 years as Chief of the Biophysics Laboratory, during which time he brought a number of physical chemical methods, including NMR spectroscopy, laser light scattering, and computational chemistry (molecular modeling) to CBER for the characterization of biological macromolecules.

Dr. Egan received his PhD in Chemistry from Princeton University and was a post-doctoral fellow in the Division of Physical Chemistry and the Lund Institute of Technology in Sweden. Prior to joining FDA, Dr. Egan was a Senior Staff Fellow at the National Institutes of Health. Dr. Egan is an author or co-author of over 100 scientific papers, primarily in the study of macromolecular structure and function. Dr. Egan is a member of a number of professional organizations, including the American Chemical Society and the International Association of Biologists, where he is vice-chair of the Human Vaccine Committee.

Christopher Eisenschenk, PhD
Shareholder

Saliwanchik, Lloyd & Saliwanchik

Dr. Eisenschenk joined Saliwanchik, Lloyd & Saliwanchik in 1999 where he is now a shareholder. Prior to his association with the firm, Eisenschenk was a supervisory patent examiner in the biotechnology groups at the United States Patent and Trademark Office (USPTO) and he was detailed to the Board of Patent Appeals and Interferences to review appealed applications. His practice largely focuses on securing and exploiting intellectual property protection for biological, biotechnological, chemical and pharmaceutical inventions in the United States and overseas. Eisenschenk has successfully represented clients in licensing negotiations, reissue proceedings, re-examination proceedings and due diligence analyses regarding potential acquisitions. He has also prepared freedom to operate and non-infringement opinions for various clients. Representative clients include both large and small companies in the biotechnology and pharmaceutical space as well as universities and independent inventors. He is licensed to practice before the USPTO and is admitted to the Maryland and Florida Bar.



Ruden McClosky

The Intellectual Property Law Practice Group

Ruden McClosky is a full-service Florida law firm. Our attorneys represent large and small businesses, academic institutions, not-for-profit organizations and individuals in all matters related to Intellectual Property

Stanley A. Kim, Ph.D., Esq.
222 Lakeview Avenue
Suite 800
West Palm Beach, FL 33401
(561) 838-4512
Stanley.Kim@ruden.com

www.ruden.com

FT. LAUDERDALE ■ MIAMI ■ NAPLES ■ ORLANDO ■ PORT ST. LUCIE ■ ST. PETERSBURG
SARASOTA ■ TALLAHASSEE ■ TAMPA ■ WEST PALM BEACH ■ CARACAS, VENEZUELA

www.higventures.com



With over \$550 million of dedicated venture capital under management, H.I.G. Ventures invests nationally in early to growth-stage information technology, life sciences and service businesses.

H.I.G Ventures is the venture capital affiliate of H.I.G. Capital, a leading investment firm with over \$4 billion of capital under management and offices in Miami, Atlanta, Boston, San Francisco, London, Hamburg and Paris.

ATLANTA (404) 504-9333 MIAMI (305) 379-2322



Scott Ellington
Executive Director
Florida Atlantic Research and Development Authority

Scott Ellington has been executive director since December of 1998. He has the responsibility for Research Park development and operations in Boca Raton and Deerfield Beach. 27 active companies and 17 Incubator companies are growing in these

high-tech development parks. Prior to this he was the Director of Development for the College of Education at FAU.

Scott was what he calls an itinerant worker for IBM for 30 years, serving as Manager of Marketing Training in Dallas, Branch Manager for New Jersey, manager of Competitive Marketing, and National Sales Manager for Office Systems in Atlanta. His last IBM job was as Florida Sales Manager for the Education Industry, where he came to know FAU. He also served as a consultant on education marketing to the Honeywell Corp. Scott helped to create a research park for The University of the US Virgin Islands, as well as one in Illemau Germany for the new government of unified Germany, to fortify the Economic Development in the old “East Germany”. He has helped create Research Parks at Auburn University and at the UF campus at Port St. Lucie, as well as at the University of South Alabama in Mobile.

In community service: Scott is very active in Literacy, and served as a Board member of his Boca Sunrise Rotary Club, served as District Rotary Chair for Literacy, and sponsors young Rotarian service organizations at the High School and College levels. He is a three time recipient of the Rotary “Service above self” award. He served as the Chair of the Governors’ Council on Community Involvement in Schools.

He is currently the State Chair of the Governors Family Literacy Initiative. He is very proud of his two married children and 4 grandchildren. Scott is a very serious boater, with a 50 ton offshore Masters License and multiple USCG certifications; he is serving as the operations officer for the US Coast Guard Auxiliary.

Stephanie C. Finnegan
CEO
Goodwin Biotechnology

Stephanie Finnegan founded Goodwin Biotechnology, Inc. in 1992, as a spin-off of the Goodwin Institute for Cancer Research. Accordingly, GBI is the oldest biotech company in Florida, and Florida’s only non-university contract manufacturing organization



(CMO). In its history, GBI has served more than a hundred clients from all over the world, and has manufactured more than 330 different mammalian cell lines for clinical phases I, II and III.

Ms. Finnegan is a former Ernst & Young CPA, and also spent a number of years consulting for a McKinsey spin-off consulting firm in the Northeast. At this firm, she consulted primarily to large pharma, and developed a fascination with the field of contract manufacturing in the pharmaceutical industry. Thus, it was a logical step to found GBI, one of the world’s first biologics CMOs.

Mike Fisher, PhD
Life Sciences Sector Specialist
UK Trade and Investment


Mike began his scientific career with the Defence Evaluation and Research Agency (DERA) at CBD Porton Down, developing ligands as biosensor receptors for the detection of toxins and pathogens. Remaining at CBD he became Project Manager for the Agency’s ‘blue sky’ research into biological detection, with an annual research budget of c\$5M.

In September 2000 he joined Bionow as the Biotechnology Project Manager, where he developed a number of sponsorship deals for Bionow’s activities and was a founder of NowGen, the NW Genetics Knowledge Park. After two years in this role he moved to Pera Innovation as a consultant where he initiated the UK-Texas Collaboration in Bioscience for the Department of Trade and Industry’s Bioscience Unit and also assisted UK companies access European research funding. He returned to Bionow in February 2004 to head the international aspects of Bionow’s activities and develop the group’s international strategy. Joining UKTI in November 2005, Mike is now responsible for advising its US and Canadian network on life science issues and opportunities for the UK.

Mike has a PhD in HIV Protease Inhibition and has produced several scientific publications and one patent from his research.

Mary Freeman
Co-Founder and President
Awareness Technology

Mary Freeman came to Florida with a BS in biochemistry from the University of Maine. After graduate studies at the University of Miami School of Medicine she co-founded Awareness Technology with her husband, Gary, in 1982 and has been president of the company since then. Awareness Technology designs and manufactures laboratory instruments such as biochemistry analyzers and immuno-assay equipment mostly for use in clinical diagnostic use. In 1989 the company made its first attempts at exporting. Over the years they developed a network



Looking to Attract and Retain World-Class Research Staff?

Talk to Talka.



A well-designed facility is crucial to helping you attract top recruits, acquire grants and prompt investments. With so much at stake, you need a specialized design expert to plan and design your research facilities. Few people have as much experience in research design as Jeff Talka.

Talk to Jeff about how GS&P can help you with your next facility project.

Jeff Talka, AIA, LEED AP

813.251.6838

jeff_talka@gspnet.com

www.gspnet.com



G R E S H A M
S M I T H A N D
P A R T N E R S

ARCHITECTURE • ENGINEERING • INTERIOR DESIGN

Serving Florida from Jacksonville, Tampa, and Ft. Lauderdale

FL REGISTRATION • AAP000034 • EB0003806 • IB26000797

Serving Clients Across the Globe >



Fuerst Humphrey Ittleman brings together specialists in the following fields:

Taxation

Tax Litigation

Food, Drug and Cosmetic Law

Customs Law

International Trade Law

Commercial Transactions

Sarbanes Oxley

FTC Advertising

Corporate Compliance

Banking Regulation

Complex Commercial Litigation

Anti-Money Laundering Compliance

White Collar Criminal Defense

Healthcare

1001 Brickell Bay Drive, Suite 2002, Miami, Florida 33131
Telephone: 305.350.5690 Fax: 305.371.8989

www.fuerstlaw.com



**FUERST
HUMPHREY
ITTMAN**

Attorneys and Counselors at Law

The hiring of a lawyer is an important decision that should not be based solely upon advertisements. Before you decide, ask us to send you free written information about our qualifications and experience.

of distributors covering more than 100 countries. In year 2000 they opened an office in Dubai to better serve their Middle East customers. Awareness Technology now exports more than 70% of their annual production; and their brands are known worldwide within their industry.

The Freemans and Awareness Technology have received many business recognitions including the President's E Star-Award for Excellence in Exports, Martin County Business Woman of Distinction, and State of Florida Governor's Business Diversification Award in Export Excellence, as well as State and National New Product Design Awards for innovative engineering.



Mitchell S. Fuerst
Managing Partner
Fuerst Humphrey Ittleman

Mitchell S. Fuerst is a founder of Fuerst Humphrey Ittleman, PL and is the firm's managing partner. He concentrates his practice in the areas of tax law and tax litigation, corporate governance and compliance, international business transac-

tions, complex commercial litigation, international trade law, mergers and acquisitions, securities law and banking regulation. Fuerst's practice is primarily devoted to the comprehensive representation of businesses. His ability to thoroughly assess and analyze the strategies and goals of corporations, coupled with nearly 30 years of diverse legal experience, places him in a unique position to effectively guide businesses through the complexities of governmental regulations and corporate compliance requirements while consistently maximizing shareholder value. Fuerst often works in conjunction with corporate executives to develop ambitious long-term and short-term business strategies that meet or exceed all legal requirements while simultaneously promoting the growth and success of the corporation.

Prior to founding Fuerst Humphrey Ittleman, PL, Fuerst was the founding shareholder of Rodriguez O'Donnell Ross Fuerst Gonzalez Williams & England, P.C. After leaving his position as general counsel of the largest exporter of computer products to Latin America, he formed that firm from the groups of outside attorneys who he had used as general counsel. He commenced the FDA practice of the firm with Christine Humphrey, a founding partner of Fuerst Humphrey Ittleman, PL, in the Miami office of that firm.



Franklin Garcia-Godoy, DDS, MS
Professor and Associate Dean of Research
Director of the Clinical Research Center
Director of the Bioscience Research Center
Nova Southeastern University
Franklin Garcia-Godoy has been at Nova Southeastern

University College of Dental Medicine (NSU-CDM) for 5 years. Previously he was at the University of Texas Health Science Center at San Antonio and at Tufts University in Boston. During his short-time at NSU-CDM he has brought over \$3.7 million in research funding through a diverse range of projects including biomaterials development, stem cells and tissue engineering and consumer product testing. His most recent project was awarded \$1 million from the National Institutes of Health to develop new materials biocompatibility testing methods to avoid animal experimentation.

His specialist training was in pediatric dentistry and he has been a leading advocate of introducing new dental treatments, and biomaterials to help improve the lives of children, teenagers and adults. He has authored several widely-used text books and his most recent book: "Primary Preventive Dentistry" is in its 6th edition. He is best known for being the Editor of the *American Journal of Dentistry*, which is one of the most respected scientific journals in dentistry. He is also Associate Editor of the *Journal of Dentistry* and also Associate Editor of Stem Cells and Development.

He collaborates with researchers located in universities all over the world and over the years has helped train and educate many dentists who serve communities across the U.S. and abroad.

At a national level, he is a member of several National Institutes of Health study sections (review panels) and on the advisory boards of several large companies. Locally, he has been active on the board of advisors for the College of Engineering of Florida International University, in Miami, Florida, and is a co-founder and co-chair of the South Florida Bioscience Consortium, a branch of BioFlorida, which promotes the Florida bioscience industry.

Reza Ghafoorian, MD
Partner
Hansen Huang Technology Law Group



Reza Ghafoorian is an experienced patent attorney as well as a medical doctor. In addition, Dr. Ghafoorian is an experienced entrepreneur having co-founded Global Identity Bank, LLC.

Dr. Ghafoorian is also a named inventor of a patent application dealing with biometric identification and storage. Prior to becoming a partner at Hansen Huang Technology Law Group, Dr. Ghafoorian was an assistant state attorney for the Office of State Attorney, 17th Judicial Circuit, Florida, where he litigated a wide variety of cases for the State Attorney's office as a first chair prosecutor. Dr. Ghafoorian has particular experience in drafting and prosecuting patent applications in the medical devices, biotechnology, pharmaceuticals and mechanical arts. Dr. Ghafoorian received his Medical degree and a Law degree from The George Washington University.

Your job is *innovation.*

Ours is helping you *succeed.*

Join BIO and tap into the world's largest biotechnology network. We are 1,200 members strong and offer services you can't find anywhere else:

- Advocacy in Washington, state capitals and international forums.
- Business development conferences, executive training and other services.
- Discounts on business essentials through our group purchasing program.

Visit bio.org/join to apply for membership.



1201 Maryland Avenue SW • Suite 900 • Washington, DC 20024 • 202.962.9200 • www.bio.org



**Contributing to the
prevention and cure of cancer.**



1-888-MOFFITT | www.moffitt.org



A DEPTH OF RESOURCES.

L I F E S C I E N C E S

At EAPD, we have the depth of legal resources that you need to fund, commercialize and patent your discoveries—all in one firm. In fact, we've been doing this in the life sciences industry from the beginning. As a *Global 100* law firm, our life sciences group has what it takes.

Turn on the power

EDWARDS
ANGELL
PALMER &
DODGE LLP

eapdlaw.com

BOSTON | FT. LAUDERDALE | HARTFORD | NEW YORK | PROVIDENCE | SHORT HILLS
STAMFORD | WASHINGTON DC | WEST PALM BEACH | WILMINGTON | LONDON (*Representative Office*)

ATTORNEY ADVERTISING. The hiring of an attorney is an important decision that should not be based solely on advertisements. Prior results do not guarantee a similar outcome.

Kelly Gridley, PhD
Coordinator Biotechnology
Laboratory Technology Program
Santa Fe Community College

Kelly Gridley worked as a Medical Technologist at Shands Hospital at the University of Florida from 1987-1990, when she chose a career in industry. She worked at Baxter MicroScan, (now Dade MicroScan), a medical diagnostics company in Sacramento, CA, as a Technical Trainer from 1990-1992. This experience led her to academics and research, and she entered graduate school at the University of Florida in 1994. She received her degree in Pharmacodynamics in 1999, and is co-inventor on 2 patents, one of which is currently licensed. After the development of a latex allergy ended her efforts in research, she took a position at Santa Fe Community College as the Coordinator for the Biotechnology Laboratory Technology Program and during her tenure at Santa Fe Community College has tripled the number of graduates entering the workforce from that program. Her varied background in clinical and research laboratories, as well as her time in industry, give her a unique advantage in her current position.

Jo Anne Goodnight
SBIR/STTR Program Coordinator
National Institutes of Health



Prior to joining the Office of Extramural Research in 1999, she served in positions encompassing research, program administration and program management. During her 25 years of government service she has held positions in the U.S. Department of Agriculture (USDA), the Food and Drug Administration, and now the NIH. As part of her Virginia Tech education (1978-1983), she spent four years conducting research as a Cooperative Education student at the USDA's Animal Parasitology Institute. While at NIH, she has been a part of the National Cancer Institute's (NCI) Intramural Research Program as a research scientist (1989 – 1994) and the NCI's Extramural Research Program (1994 – 1999). As an intramural scientist, she published over 20 studies about the selective involvement of Protein Kinase C in differentiation and neoplastic transformation. She joined the NCI's Extramural Research Program in 1994 where she served as a Special Assistant to the Director, Division of Cancer Biology and Program Director for SBIR/STTR grants that supported studies in the field of cancer biology, cancer genetics, and cancer immunology as well as the SBIR/STTR Program Policy Coordinator for the entire NCI. She was appointed as the NIH SBIR/STTR Program Coordinator in 1999

WE UNDERSTAND YOUR WORLD

Lott & Friedland is a Florida Intellectual Property law firm founded in 1983 with offices in Miami and Fort Lauderdale, Florida. We are now celebrating our 24th year of providing clients with legal advice. Our attorneys concentrate their practice on all aspects of intellectual property law, including patents, trademarks, copyrights, the Internet, entertainment law and related litigation.

The protection of intellectual property is critical for biomedical products which generally require some level of market exclusivity to assure return on investment. The single most valuable asset of a biomedical company is usually its intellectual property as evidenced in the scrutiny that inventions, patents, trade secrets, trademarks, copyrights, etc., receive in any transaction. Intellectual property gets judged at every step and turn from bench top to market and beyond.

Our attorneys have practical experience in the therapeutic, device and diagnostic fields. We understand the path that an NDA, ANDA, 510(k), PMA, or biologic product must take to market and can evaluate a product for protectable subject matter and/or infringement at the relevant time points during the development and life cycle.

We can assist you with:

- **Intellectual Property Acquisition, Sale and Due Diligence.**
- **Drafting and Prosecution of Patent and Trademark Applications.**
- **Intellectual Property Opinions.**
- **Enforcing and Defending Your Rights.**

Contact:

Michael J. Keller (954) 315-5044 or (305) 448-7089
mjkeller@lfiplaw.com

MIAMI OFFICE:
355 ALHAMBRA CIRCLE
SUITE 1100
CORAL GABLES, FLORIDA 33134
305/448-7089 TELEPHONE
305/446-6191 TELECOPIER
HTTP://WWW.LFIPLAW.COM

FORT LAUDERDALE OFFICE:
ONE EAST BROWARD BOULEVARD
SUITE 1609
FORT LAUDERDALE, FLORIDA 33301
954/315-5044 TELEPHONE
954/315-5045 TELECOPIER

GROWING INDUSTRY GROWING COMMUNITY

The Metro Orlando Economic Development Commission is proud to announce establishment of **bioOrlando**, the Central Florida Chapter of BioFlorida. This volunteer-led council is dedicated to accelerating growth of the life science industry in Central Florida.

bioOrlando will build on momentum arising



from the establishment of the new UCF College of Medicine and the Burnham Institute's east coast research facility. Together, we are working to make our region a preferred destination for healthcare, life science, biotech, and pharmaceutical companies, as well as other supporting industry.

For more information,

go to www.bioOrlando.com



PROUD PARTNERS IN BUILDING
CENTRAL FLORIDA'S TECHNOLOGY INDUSTRY

where she continues today. She was intimately involved in the development and implementation of the NIH SBIR/STTR Fast-Track Program and continues to develop other programs that assist the small business community in commercialization of their technologies. She has been an invited participant in numerous SBIR/STTR Conferences to discuss funding opportunities for small businesses through the NIH. She also has provided written and oral testimony at Congressional hearings related to the reauthorization of the SBIR and STTR Programs. Ms. Goodnight has received several national awards including NIH Director's Awards, NIH Merit Award and the Small Business Administration Tibbetts Award. Ms. Goodnight received a Bachelor of Science degree in Microbiology from Virginia Tech in 1983.



Libby Handel, PhD
Director of Biotechnology Programs
Palm Beach Community College

Libby Handel is presently charged with creating and implementing a new Biotechnology Program to meet the workforce needs of our emerging bioscience community. She received her PhD in Experimental Pathology at the University of Colorado specializing in mechanisms of gene transcription and breast cancer research.

Her research involved investigating antiprogestins for the treatment of breast cancer and discovering novel signaling pathways of steroid hormones. She has worked as an Industry Agreement Specialist in Corporate Sponsored Research and Licensing at the Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, and served as an independent biotechnology consultant to early-stage companies. Libby is a mother of three and also serves as Vice President of The Pink Purse, a non-profit organization devoted to inspiring women to make a difference in their community.



Robert M. Hansen
Partner
Hansen Huang Technology Law Group

Bob Hansen is a founding partner of Hansen Huang Technology Law Group, LLP. Mr. Hansen has extensive experience in all aspects of patent law including patent preparation and prosecution; patentability, validity, and infringement opinions; strategic patent portfolio development; litigation; and licensing. Mr. Hansen's practice focuses on patent prosecution, litigation, client counseling and licensing in the areas of medical devices, electronics and systems, computer software, materials and mechanical systems. Prior to Mr. Hansen's legal career Mr. Hansen had experience as an engineer, program manager and business executive with

Fortune 100 companies, as well as startup companies, including Protiveris, Inc., a biotechnology startup company where he was in-house patent counsel. With experience in business acquisitions and divestitures, patent portfolio management and managing engineering teams, Mr. Hansen understands the business realities as well as the technology. Mr. Hansen received a Master's degree in engineering from University of Florida and a Law degree from George Mason Law School.

Joshua M. Hare, MD
Director of the Interdisciplinary Stem Cell Institute
Chief of Cardiology and Louis Lemberg Professor of Medicine
University of Miami Miller School of Medicine

Dr. Hare received his BA at University of Pennsylvania and his MD at Johns Hopkins University. He completed fellowships at Johns Hopkins University and Brigham and Women's Hospital in Boston. He was a Research Fellow at Harvard University. He is Board Certified in Internal Medicine.

Mark Hefferin
Executive Vice President and Head of Operations
BE&K Building Group

Hefferin has more than 25 years in construction experience with the majority of that time devoted to projects dealing with the life sciences. As Executive Vice President, Mark oversees marketing, preconstruction and operations in Florida. His responsibilities also include leadership through short and long-range strategic planning initiatives, in alignment with company strategies. Mark is involved with the Design-Build Institute of America, International Society of Pharmaceutical Engineers, Associated Builders and Contractors, Inc. and the Orlando Chamber of Commerce. He is currently working on projects for the Burnham Institute, Florida State University, the Ginn Company, Seminole County Public Schools and Simon Property Group. He has completed projects for Eli Lilly, Rhodes Technologies, Covance Biotechnology Services, Novo Nordisk Pharmaceutical Industries, the Institute for Scientific Research (ISR) and many others.

Richard A. Houghten, PhD
President
Torrey Pines Institute for Molecular Studies

Richard A. Houghten is internationally recognized as an expert in the use of molecular diversity and combinatorial methods in the drug discovery process. He has authored or co-authored over 550



scientific publications and has been issued 70 U.S. patents. His work led to one approved diagnostic product and three compounds moved through various levels of human clinical trials. Dr. Houghten received his BS in Chemistry from California State University at Fresno (1968) and his doctorate in organic chemistry from the University of California, Berkeley (1975).

In 1989 Dr. Houghten founded the Torrey Pines Institute for Molecular Studies (TPIMS), a not-for-profit research center dedicated to discovering treatments for multiple sclerosis, heart disease, arthritis, cancer, HIV/AIDS, pain modulation and infectious disease. In 1986, he founded Multiple Peptide Systems (NeoMPS) a for-profit company to make synthetic peptides available to the research community. Dr. Houghten also started Trega Biosciences which became publicly traded in 1995 and most recently Mixture Sciences Inc. Currently he is the Director of TPIMS, the CEO of Mixture Sciences, the CSO of NeoMPS and an adjunct Professor at Zhejiang University in Hang Zhou, China.

Dr. Houghten has received numerous awards including the first Athena Individual Pinnacle Award in 1999 for Empowering and Promoting Women, the Vincent du Vigneaud Award for Excellence in Peptide Science (2000), the K. Puang-piu Chair Professor at Zhejiang University (Hangzhou, China 2004), the American Chemical Society Ralph Hirschman Award (2004) and the 2005 Bruce Merrifield Award from the American Peptide Society.

Christine M. Humphrey **Founding Partner** **Fuerst Humphrey Ittleman**



Having 14 years of Food & Drug Administration (FDA) experience, Ms. Humphrey focuses her legal practice on FDA matters, including domestic and foreign inspections of all FDA-regulated products; import and export processes; criminal, regulatory

and administrative actions; risk management, regulation and agency guidance development; and issues related to the FDA's new bioterrorism rules and guidance.

Ms. Humphrey has extensive experience in handling matters involving FDA imported products that are the subject of FDA administrative or Customs' civil enforcement (seizure, monetary penalties, or claims for liquidated damages) and criminal investigations related to smuggling. Ms. Humphrey has successful criminal prosecution experience with respect to smuggling of illegal products into the U.S. and has served as co-counsel with the Department of Justice. In addition, she has in-depth knowledge, as an FDA investigator and a compliance officer, of FDA food, drug, medical device (Quality Systems Regulations), radiological health, biologics, cosmetics, Investigational Review Boards (IRBs), clinical investigations and HACCP requirements.

Sharon Isern, PhD **Associate Professor** **Florida Gulf Coast University**

Sharon Isern is an Associate Professor in the Department of Biological Sciences and a member of the Biotechnology Research Group at Florida Gulf Coast University. She received her BS in Chemical Engineering from The Johns Hopkins University and her PhD in Biochemistry and Molecular Genetics from the University of Alabama at Birmingham. Dr. Isern's research interests include the study of viral entry pathways, the development of molecular tools for the transgenesis of invertebrates, and the development of novel antiviral entry inhibitors and vaccines. Dr. Isern has received research support from the NIH, NSF, DOD, USDA and several private foundations and biotechnology companies.



Patrick R. Kay **Director of Florida Operations** **Alexandria Real Estate Equities, Inc.**

In his role as director, Patrick manages the day-to-day operations for the company in Florida including business development, acquisitions, property development and redevelopment, and asset management activities. Most recently, Patrick's main focus has been the development of a first-class laboratory facility near the new Scripps Florida campus in Jupiter. The property will allow Alexandria to serve the diverse needs of start-up and early stage companies in the region's developing life science community. The facility will include fully fit-up, turn-key office/laboratory suites with a full range of operational and service amenities available, which include shared support equipment, conference facilities, on-site building support and management, and a host of additional specialty services.

Prior to initiating Alexandria's presence in Florida, Patrick performed similar functions in Cambridge, Massachusetts as a Project Manager for Alexandria. Patrick began his professional career with Navigant Consulting, Inc., based in New York City and later Boston. In this capacity Patrick provided management and litigation consulting services focused primarily on the real estate, construction, and government contracts arenas.

Patrick is a graduate of Tufts University where he received a Bachelor of Science in Environmental Engineering.



**BURNHAM INSTITUTE
for MEDICAL RESEARCH**
From Research, the Power to Cure

Burnham Institute for Medical Research

Conducting world-class research
in three locations:

*La Jolla, California
Santa Barbara, California
and now
Lake Nona in Orlando, FL*

Florida Pipette Calibrations

- On-Site Pipette Calibration & Repairs
- 12+ Years Experience
- All Brands of Pipettes Serviced
- Calibration Reports To Fit Your Requirements
- Professional and Reliable
- We Work With Your Budget
- NIST Traceable
- Comply with GMP, GLP, CLIA, ISO, FDA, CAP, NCLLS



*Debbie Marcellino,
Owner*

Certified Woman Owned Business

BioFlorida Member

toll-free: 1-866-FLPIPET (1-866-357-4738)
flpipet@aol.com • www.floridapipettecalibrations.com

Gainesville, FL - Tampa, FL - Madison, WI - Chapel Hill, NC - Seattle, WA

engineering excellence

University of Florida
Biomedical Sciences Building

**AEI Affiliated
Engineers**

www.aeeng.com

Walnut Creek, CA - Metro DC, MD - Houston, TX - Chicago, ILL

naturejobs.com

UP, UP AND AWAY...

With **4,000*** science vacancies on **one** site, naturejobs.com is now the largest dedicated job board for the scientific community.

And it's free to post all your vacancies online at www.naturejobs.com/postmyjob

**WHAT ARE YOU WAITING FOR?
Go to naturejobs.com or telephone:**

Helen Wu
T: 212 726 9347
E: h.wu@natureny.com
*Total jobs in database 6 July '07

nature publishing group

The Premier Source for Business Assistance

Florida Small Business Development Center Network



Profit From Our Experience



Business Technology Commercialization for *Physical and Life Sciences*

- Links SMEs to needed resources
- Serves as catalyst to investors
- Locates sources of venture capital
- Facilitates technology transfer
- Reviews strategic and business plans
- Assists with R&D funding
- Supports economic development
- Assesses technology & innovation

**BTC—Accelerates the
Commercialization of Technology**

30 Plus Years Helping Businesses

Start, Grow and Succeed

Counseling • Training Events • Business and Research Information

BTC is a specialized program of the FSBDCN, a statewide network of 35 centers funded in part through a cooperative agreement with the US SBA and hosted by UWF.

www.FloridaSBDC.com

850.473.7805

Winner of the National EDA Excellence Award for Economic Adjustment Strategies



Michael J. Keller

Shareholder
Lott & Friedland

Mr. Keller heads the biomedical practice group for the intellectual property law firm of Lott & Friedland. Mr. Keller has extensive experience in law firm, government and corporate settings. This includes three years of government technol-

ogy transfer experience with the Department of Energy and the National Cancer Institute. He also served the dual role of intellectual property and FDA associate in the Washington, DC office of a multinational law firm where he advised clients on issues of intellectual property and food and drug law and related litigation before the Federal Courts and International Trade Commission. Over the last eleven years he has started and run the patent departments for both IVAX Corporation and most recently GMP Companies where he held the title of Chief Patent Counsel. He has been the lead negotiating and drafting attorney on hundreds of transactions including complex licenses, asset purchases, sponsored research, contract research and clinical trial agreements with large and small companies and universities around the world. He has developed intellectual property enforcement and defense strategies for both branded and generic biomedical products. His present practice includes the representation clients on patent and trademark prosecution, transactions related to intellectual property and biomedical product development and strategic advising. Mr. Keller received his Biology and Law Degrees from the University of Georgia and completed two years of coursework in the Molecular Biology Program at The George Washington University.

Patrick M. Kelly
Vice President for State
Government Relations and
Alliance Development
Biotechnology Industry
Organization (BIO)



BIO is a national trade organization representing more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 states and 33 nations.

BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. Patrick is responsible for state legislative and regulatory activity in all 50 states. In addition he oversees BIO's alliance development efforts, working with patient advocacy groups and various other organizations to promote the biotechnology industry.

Patrick works with biotechnology companies and allied groups to develop and communicate industry policies on a variety of state issues including economic development, healthcare, bioethics, agriculture as well as renewable fuels and industrial biotechnology. In the states, BIO works closely with the Council of State Bioscience Associations (CSBA), a network of state-based bioscience organizations, to advance state support of the biotechnology industry.

Prior to joining BIO in 1995, Mr. Kelly was a Representative for State and Environmental Affairs with the Grocery Manufacturers Association. Mr. Kelly is a graduate of the University of Maryland.

Stanley A. Kim, PhD

Partner
Ruden McClosky

Stanley A. Kim is a graduate of Bowdoin College (A.B., 1987) and received his law degree from Suffolk University Law School (JD, magna cum laude, 1998). He also holds a PhD in Microbiology and Immunology from the University of Miami (PhD, 1993).



A member of the Firm's Intellectual Property Practice Group, Dr. Kim concentrated his practice in all facets of intellectual property including patents, trademarks, copyrights, trade secrets and transactions relating to intellectual property. He advises corporate, academic and individual clients on all aspects relating to the development, acquisition and use of intellectual property.

A registered patent attorney, Dr. Kim has extensive experience in assisting clients in procuring domestic and foreign patents in a wide range of disciplines including biotechnology, pharmaceuticals, organic and polymer chemistry, nanotechnology, medical devices, diagnostic assays, surgical tools, prostheses, complex machines, business methods, computer-implemented algorithms, Internet technologies and new designers. He also assists clients in securing trademark and copyright registrations, and in protecting trade secrets.

Dr. Kim also counsels clients in connection with technology transfer transactions such as licensing and joint ventures, intellectual property opinions and due diligence, strategic patent portfolio development, and intellectual property litigation matters.

Dr. Kim is a member of The Florida and Massachusetts Bars and is admitted to practice before the U.S. Patent and Trademark Office, the U.S. Court of Appeals, Federal Circuit and the U.S. District Court, Southern District of Florida.

Fresh out of the oven.. that is how hot our ideas are

Hit the world running ^{UK}



The UK is not only number one in Europe for R&D, but also a global leader in converting world-class innovation into commercial reality.

At UK Trade & Investment we understand your business partnering needs. Our teams throughout the US and the rest of the world are uniquely placed to plug you into UK expertise.

For more information
please contact:

Ximena Prella
Ximena.Prella@fco.gov.uk
305-374-1522 ext.2304

Sian Shanahan
Sian.shanahan@fco.gov.uk
305-374-1522 ext.2302

UK Trade & Investment is the Government organisation that helps UK based companies succeed in international markets. We assist overseas companies to bring high quality investment to the UK's vibrant economy.

www.uktradeinvest.gov.uk or Visit us at BioFlorida 2007

UK
TRADE &
INVESTMENT 



Kenneth B. Kirby
President and Founder,
TransDermal Technologies

Mr. Kirby founded TransDermal Technologies in 1990 and has overseen both operations and technical development for Transdermal Technologies. He is the co-inventor of the TDS(r) technology. In the late 1980s, he identified a novel

transdermally active pharmaceutical compound, negotiated a license for its patents, raised the seed capital and subsequent mezzanine financing, formulated the product, designed the packaging, engaged its manufacturing and began marketing the product in the United States. Mr. Kirby received a BA in pre-medical studies from Florida State University with an emphasis in clinical psychopharmacology. He is a member of Phi Beta Kappa and the American Chemical Society. Kirby also is a Paul Harris Fellow of the Rotary International Foundation and serves on the Board of Advisors of the Jim Moran Institute for Global Entrepreneurship at Florida State University.

Michael A. Kolber, MD, PhD
Professor and Director
Clinical Immunology, Department of Medicine
University of Miami Miller School of Medicine

Dr. Kolber received his Doctor of Medicine from the University of Illinois. He then went to Jackson Memorial Hospital for his residency, followed by his fellowship at the Experimental Immunology Branch of the National Cancer Institute at the National Institutes of Health in Washington, D.C. Dr. Kolber's clinical interests include infectious diseases, compromised host infections, HIV/AIDS and cellular immunology, and his research interests include cellular immunology and immune pathology of HIV.



Andrew J. Kurtz, PhD
Office of the Director
National Cancer Institute

Dr. Kurtz is a Project Manager in the SBIR Development Center at the National Cancer Institute (NCI). This newly-created office serves as NCI's focal point for the management of all Small Business Innovation Research (SBIR) and Small

Business Technology Transfer (STTR) program initiatives. Previously, Dr. Kurtz was a AAAS Science & Technology Policy fellow at the NCI, where he evaluated NIH SBIR program policies and played a key role in the development of new strategies to advance emerging technologies toward commercialization. He holds a BS in Chemistry from The University

of Texas at Austin and a PhD in Human Biological Chemistry and Genetics from The University of Texas Medical Branch at Galveston. Dr. Kurtz has nine years of combined research and development experience in both academic and industrial settings.

Stuart M. Langbein
Partner
Hogan & Hartson

Stuart Langbein's practice focuses on the regulatory aspects of the health care industry, with an emphasis on counseling clients on coding and reimbursement issues, particularly related to new medical technologies and health care fraud and abuse. Stuart's clients include pharmaceutical companies, medical device companies, health care product and provider associations and academic medical centers.

Prior to joining Hogan & Hartson in 1997, Stuart served in the Office of the General Counsel for the U.S. Department of Health and Human Services, representing the Centers for Medicare & Medicaid Services (CMS), then the Health Care Financing Administration (HCFA). During his nearly six year tenure with the agency, Stuart drafted briefs and presented oral arguments on the agency's behalf before federal district and appellate courts. In addition, Stuart counseled CMS extensively on Medicare reimbursement issues.

Stuart is active with the Juvenile Diabetes Research Foundation, focusing on various government relations initiatives. Stuart frequently speaks on reimbursement issues concerning providers and medical technology manufacturers.

Mick Lasher
President
Lasher Associates

Mick Lasher founded Lasher Associates in 1985, and currently serves as President of the firm. He is a renowned expert on recruiting, with particular expertise in all forms of technology and the unique challenges facing emerging companies. Mick has been a Director of the Florida Venture Forum since 1986 and served as Chairman in 1992, the inaugural year of the Annual Florida Venture Capital Conference. He is a past President of a local chapter of the Society of Human Resources Management and served as Adjunct Professor in the MBA program at Florida International University.

Mick is also past Director and Vice Chairman of Enterprise Development Corporation of South Florida, a public/private developer of emerging companies. He has served on the



corporate boards of Unipower Corporation, a Florida-based manufacturer of electronic power supplies, and StrandWare, Inc., a leading developer of barcode software headquartered in Wisconsin.

Mick began his human resource management career with Coulter Corporation (now Beckman-Coulter). He then joined Fleming Associates, a nationally renowned retained executive search firm, as a partner. Mick earned a BS in Business Administration from the University of Florida, attended graduate studies at Golden Gate College, and served four years in the United States Air Force.

Larry Lemanski
Vice President for Research
Florida Atlantic University

Dr. Lemanski is Florida Atlantic University's (FAU) first vice president for research. He also serves as President and Chair of the FAU Research Corporation. In addition, he is a professor of biomedical sciences, a professor of biology and a professor of chemistry. A prolific researcher in the field of cellular, molecular and developmental biology, Dr. Lemanski has numerous research publications, book chapters and proceedings to his credit, as well as many presentations at national and international conferences.

Since coming to FAU in 2001, Dr. Lemanski has established the university's division of research, incorporating the offices of the vice president, sponsored research (pre-award), con-

tracts and grants (post-award), technology transfer and the Florida Atlantic University Research Corporation. Under his leadership, FAU has more than doubled its level of research funding during the last four years and has been classified by the Carnegie Foundation for the Advancement of Teaching as a "Research University—High Research Activity" institution. Other significant research milestones at FAU since his appointment include the establishment of the Center of Excellence for Biomedical and Marine Biotechnology and the newly formed Center of Excellence in Ocean Energy Technology. Dr. Lemanski organized and served as principal offeror for both of these Centers.

Dr. Lemanski serves on the board of directors of the FAU Development Authority, Inc.; on the board of directors of the Florida Research Consortium; and is a board member of the University Alliance for Research, Education and Technology and the Florida Israel Institute. He has also served on the nationally-elected board of directors for Oak Ridge Associated Universities (ORAU) from 2000 to 2003, and was re-elected to a second term for 2004-2007. In 2004 he was named to the board of directors of the Institute for Human and Machine Cognition by former Florida Governor Jeb Bush and also to the board of directors of the Florida Space Research Institute. In 2005, he was named as "South Florida Bioscience Leader" by South Florida CEO Magazine and in 2007 he received the "World-class Faculty Award" from the Broward Alliance.

Preclinical Toxicology Services
in US and China



US Headquartered | GLP Compliant
AAALAC Accredited

Mouse | Rat | Rabbit | Dog | Monkey

www.bridgeCRO.com

Providing the
solid support your
project needs

Whether your therapeutic is on the benchtop or in the clinic, GBI provides the highest level of biopharmaceutical manufacturing support.

Goodwin Biotechnology, Inc.
From Bench to Clinic

PH +1.954.327.9654
FX +1.954.587.6378
EM gmp@goodwinbio.com

www.goodwinbio.com



A Great Discovery



Research Florida is a unique opportunity for Florida colleges, universities and private sector companies to publicize their research achievements, inventions, patents and tech transfer programs all year long.

This bi-annual publication, printed inside the **June 2008** issue of *Florida Trend* and *Business Florida* in **September 2008**, takes research to the marketplace; connecting higher education with companies seeking profitable partnerships focusing on tech transfer.

www.ResearchFlorida.com



Call now for more information or to reserve your advertising space.

(727) 821-5800

Ad Space Deadline: March 24, 2008

Materials Deadline: March 31, 2008

AMERICAN MEETINGS, INC.



AMERICAN MEETINGS, INC.

www.AmericanMeetings.com

Meetings made easy.

Creating Meetings and Events

For Small Firms

& Fortune 500 Worldwide



***Check on your event from anywhere via the internet free
when American Meetings manages your program.***

Visit our booth at the 4th Annual World Health Care Congress for a chance to win an Amex Gift Card and Bose Head Phones.

866-337-7799



Howard J. Leonhardt
Founder, Executive Chairman
and CTO
Bioheart

Mr. Leonhardt is the Founder of Bioheart and has served as Chairman of the Board and Chief Executive Officer of the Company since its founding in June of 1999. From December 1998 through June 1999 he

held the position of President of World Medical Manufacturing Corporation, a subsidiary of Medtronic, Inc. From 1986 to December 1998 he served as Founder and Chief Executive Officer of World Medical Manufacturing Corporation, a medical technology company that initially produced cardiovascular balloon catheters and later progressed into development of other products including stent grafts for aortic aneurysm repair.

He is also the Founder of World Biotech a private investment fund specializing in biotechnology companies. He graduated from the accelerated International Trade from Anoka-Hennepin Technical College, attended Anoka-Ramsey Community College and the University of Minnesota, and has received an honorary Doctorate of Biomedical Engineering degree from the University of Northern California honorary akum. Mr. Leonhardt serves as Consulting Professor and Board Advisor at Florida International University, Biomedical Engineering Institute.



Richard A. Lerner, MD
President
The Scripps Research Institute

Richard A. Lerner, MD, is the president of The Scripps Research Institute in La Jolla, CA, one of the largest private nonprofit research organizations in the United States. In addition to directing the institute's scientific activities, Dr. Lerner

is the Lita Annenberg Hazen Professor of Immunochemistry, the Cecil H. and Ida M. Green Chair in Chemistry, and a member of The Skaggs Institute for Chemical Biology at Scripps Research.

His groundbreaking research has provided a range of insights on protein and peptide structure, the identification of a sleep-inducing lipid, and the conversion of antibodies into enzymes, permitting the catalysis of chemical reactions considered impossible to achieve by classical chemical procedures. While it has taken enzymes acting on natural biological systems millions of years of evolution to reach their present level of efficiency, antibodies can be produced overnight, for obtaining an almost limitless variety of products—beyond natural ones—with an efficiency that may exceed that of natural enzymes.

Most recently, he discovered that human antibodies generate a product with the chemical signature of ozone—a highly reactive molecule never before considered part of biology. Ozone can trigger pathological changes in other molecules in the body, such as cholesterol, to produce toxic compounds. Recently, Lerner and his colleagues discovered two such compounds, which they call the “atheronals,” in atherosclerotic plaques surgically removed from patients with atherosclerosis.

Dr. Lerner graduated from Northwestern University and Stanford Medical School. He interned at Palo Alto Stanford Hospital and received postdoctoral training at Scripps Clinic and Research Foundation in experimental pathology. He has held staff appointments at The Wistar Institute in Philadelphia and at the Research Institute of Scripps Clinic (later renamed The Scripps Research Institute). He served as chair of the Department of Molecular Biology of Scripps Research from 1982-86 prior to assuming the organization's presidency.

Dr. Lerner has received numerous prizes and awards, including the Wolf Prize in Chemistry in 1994, the California Scientist of the Year Award in 1996, and the Paul Ehrlich and Ludwig Darmstaedter Prize in 2003. Dr. Lerner is on the editorial boards of several research journals and has been elected to many prestigious scientific societies, boards, and academies, including the Royal Swedish Academy of Sciences and the National Academy of Sciences. Dr. Lerner has received Honorary degrees from the following Institutes: Honorary Doctorate of Medicine, Karolinska Institute, Honorary Doctorate of Science Award Doctor Scientiarum Honoris Causa, Technion-Israel Institute of Technology, Technion City, Haifa, Israel, Doctor of Science, Northwestern University, Evanston, IL, Honorary Doctorate Degree, Ben-Gurion University of the Negev, Beer-Sheva, Israel, Honorary Doctorate in Humane Letters from Florida Atlantic University, Boca Raton, Florida, Honorary Degree of Doctor of Science, honoris causa, Oxford University, Oxford, United Kingdom.

Michael P. Levinson,
MD, JD
Counsel
Hogan & Hartson

Michael P. Levinson, MD, JD, is both a licensed physician and attorney, focusing his practice on transactional, regulatory and operational matters for corporate and individual health care clients. He is an experienced and practical attorney who draws on his business, medical and legal knowledge to help reach solutions that allow clients to satisfy their business plans and goals.

Levinson is committed to the growth of the bioscience industry. In addition to counseling bioscience clients, Levinson currently serves as Chair of the Greater Miami Chamber of Commerce Bioscience Task Force and is charged with promoting the growth and continuity of the bioscience sector throughout South Florida.



Levinson is board certified in health law by the Florida Bar. He holds medical licenses in Florida and Virginia, although he has devoted his full attention to the practice of law since 1993. He represents a wide range of clients, including hospitals, home care and other providers, medical device manufacturers, managed care companies, suppliers and physicians. Prior to joining Hogan & Hartson, Levinson was counsel in the Miami office of a well-known national law firm. Previously he served as the chief operating officer, executive vice president and general counsel of two technology-driven medical device companies.



Steven E. Lipshultz, MD
Chairman, Department of
Pediatrics
Miller School of Medicine at the
University of Miami

Steven E. Lipshultz, MD, was appointed Chairman of the Department of Pediatrics in August 2003. Dr. Lipshultz received his Doctor of Medicine from Dartmouth Medical School. He then went to Case Western Reserve

University School of Medicine for his residency in pediatrics, followed by his fellowships in clinical cardiology and research at Children's Hospital in Boston. Dr. Lipshultz most recently served as Associate Chairman of Pediatrics for Strategic Planning and Chief of Pediatric Cardiology at the University of Rochester Medical Center at Golisano Children's Hospital at Strong. Dr. Lipshultz has served on the faculties at Harvard Medical School and Boston University School of Medicine. He has been the principal investigator in a number of groundbreaking NIH studies on the causes and treatment of cardiomyopathies in children. His clinical trials have discovered therapies that can prevent heart disease in children with HIV. Another major focus of his research has been the long term heart damage that can be caused by treatments for cancer, such as chemotherapy or radiation therapy.

Jon Lourie

Partner

Edwards Angell Palmer & Dodge

Jon assists technology, science based and other companies in all aspects of achieving commercial success. He represents companies and individuals around the world in joint ventures, technology transfer, mergers and acquisitions, venture capital, international law and securities law. He is a past Co-Chair of the Firm's Technology Transactions Practice Group. Jon represents U.S. and non-U.S. biotech and medical device companies in transactions involving collaborations such as vaccines, drug delivery technologies, therapeutics, diagnostics, blood products, cardiology, antimicrobials, genomics and research tool technologies. He also represents U.S. and non-U.S. biotechnology in venture financings, acquisitions and collaborations. He advises U.S. and non-U.S. medical device companies on international and domestic joint ventures, licensing

and merger transactions. Jon is regularly involved in licensing research institution technologies to private companies for both companies and research institutions. In 2004, he represented a major university in a license to a major U.S. pharmaceutical company of a new drug treatment for hot flashes associated with menopause, as reported under "Big Deals" in IP Law and Business (January 2005).

John Lucas, PhD

Vice President of Intellectual Property
Metabasis Therapeutics

John Lucas, PhD, JP, currently serves as vice president of intellectual property for Metabasis Therapeutics. Lucas has extensive experience in managing intellectual property and providing legal assistance to biotechnology and pharmaceutical companies. Before joining Metabasis, Lucas was vice president and chief patent counsel at TransForm Pharmaceutical in Lexington, Mass. Prior to that, he served as vice president and director of worldwide intellectual property at Genset Corporation in San Diego, Calif. and Genset SA in Paris. Lucas received his doctorate in Molecular Genetics from The Ohio State University and his juris doctor from George Washington University Law School.

Sukhvir P. Mahal, PhD

Department of Infectology
The Scripps Research Institute
Scripps Florida

Graduated with a BSc in Genetics from University College London and went on to obtain a PhD in the Molecular Biology of the Prion Diseases from Imperial College, London in 1999.

She continued her post-doctorate at the Medical Research Council in Queen's Square, London in collaboration with Prof. Charles Weissmann. At the end of 2004 she relocated to join Prof. Weissmann's new department of Infectology at Scripps Florida. The group has developed a novel and powerful method to study prion diseases in tissue culture. The assay is sensitive, semi-automated and can be used to discriminate between strains of prions within 2 weeks that would normally take up to a year in the bioassay.



Gary S. Margules

Assistant Provost
Office of Technology Transfer
University of Miami

Dr. Margules has direct business experience in technology management, academic technology transfer, strategic planning, corporate ventures, R&D/project management, licensing, regulatory affairs, clinical trials and product development.



He has twenty-eight years of industry experience (eight years with Cordis Corporation as Senior Scientist, three with Pfizer Hospital Products as Assistant Director of Technology Development, three with Senmed Medical Ventures as Director, Medical Technology and fourteen with the University of Miami as Assistant Provost for Technology Transfer and Industry Research). During the past twenty-eight years he has gained in-depth knowledge in medical devices, therapeutics, biotechnology and diagnostics. He earned Doctor of Engineering Science and Master of Science degrees in chemical/bio-engineering from Columbia University and a Bachelor of Science degree in mechanical/biomedical engineering from the University of Miami.

Guy L. Mayer
President & CEO
Tutogen

Mayer is the company's President and Chief Executive Officer. Prior to Tutogen, Guy served as Chairman and CEO of Visen Medical (from 2003 to 2004), a private Biotech company focused on Molecular Imaging technologies and prior to Visen (from 2000 to 2003), as President and CEO of ETEX Corporation, a private biomedical company based in Cambridge, MA. For 13 years prior to joining ETEX, Mr. Mayer held various senior positions at Zimmer Inc., then a division of Bristol Myers Squibb, with sales in excess of \$1.2 billion. Mr. Mayer's positions at Zimmer included President Global Products Group, President Orthopedics Implant division, President Zimmer Japan and Sr. Vice President Zimmer International. Prior experience includes general management positions with Picker International in diagnostic imaging, and American Hospital Supply Corporation. Guy is a 1974 Graduate of the University of Ottawa and currently serves on the Board of Directors of Spire Corporation, a public company.



Katherine McCray
CBIZ Accounting, R&E Tax
Credit Specialist
Tax and Advisory Services

Katherine McCray is based in South Florida and is part of the CBIZ National Research and Experimentation Tax Credit Team and the CBIZ National FIN48/FAS109 Team. She has eight years of domestic and international experience in the

fields of Finance, Accounting and Taxation. She holds a Master in Taxation from the University of Denver Sturm College of Law, and a Masters of Science in Accounting and International Business from University of Colorado at Denver. CBIZ has specialists in most industries, including Bioscience and Biotechnology. CBIZ provides professional services to various businesses, individuals, governmental entities, and not-for-profit enterprises in the United States and Canada. CBIZ is the #1 benefits specialist in the US, one of the 10 larg-

est valuations firms in the US and the 8th largest Accounting Firm in the US. CBIZ National Health Care practice focuses on strategic, financial, personnel and information systems within healthcare related organizations. CBIZ ATA provides services to several industries, including VC, Construction, Not-For-Profit, Manufacturing and other Specialized Industries.

Jennifer McCafferty-Cepero, PhD
Assistant Dean for Research
Office of the Executive Dean for Research and
Research Training
University of Miami Miller School of Medicine

Jennifer M. McCafferty-Cepero, PhD, is a Research Assistant Professor in Medicine and the Assistant Dean for Research at the University of Miami in Miami, Florida. She earned her BA in Chemistry from Maryville College in Maryville, TN in 1994. In 1999, she was awarded her PhD in Molecular and Cellular Pharmacology from the University of Miami where her research centered on transcriptional gene regulation in hormone sensitive and hormone resistant prostate cancers. During her postdoctoral work, she shifted her focus to defining mechanisms of chemoresistance in hematological cancers. These studies led to her involvement in translational research projects including pre-clinical studies and clinical trial design. Following her post-doctoral training, Dr. McCafferty-Cepero worked as a Scientific Analyst and in-house cancer biology expert for a boutique law firm in New York City. In 2005, she joined the Damon Runyon Cancer Research Foundation as the Scientific Director. Dr. McCafferty-Cepero has a long-standing interest in graduate student, post-doctoral and clinical-scientist training issues, as well as in research ethics and mentoring. She is an alumna of the Graduate Research Ethics Education (GREE) program sponsored by the National Science Foundation and Indiana University and is a member of the Association for Practical and Professional Ethics. She has served as adjunct faculty at the University of Miami and at Barry University and as an invited speaker for her expertise in both scientific and research ethics issues.

Margaret J. McLaren, PhD
Head, Life Sciences Practice
Group
Carey Rodriguez Greenberg & Paul

Dr. McLaren focuses her practice in the Life Sciences and Biotechnology industries. Combining the knowledge of a seasoned academic researcher, the experience of a technology-business entrepreneur, and the skills gained over years of practice in intellectual property and business law, Dr. McLaren brings a unique perspective to her position as founder of the Life Sciences practice group at the firm. As a lawyer-scientist, Dr. McLaren recognizes that the key to creating value for clients is



an in-depth understanding of a company's technology, paired with an appreciation of the client's business goals and needs.

In her role as a registered patent attorney, Dr. McLaren works extensively with inventors to create individualized patent applications in such diverse fields as molecular biology, cellular biology, biochemistry, chemistry, pharmaceuticals, medical treatments, medical devices, diagnostics, research tools, processes and mechanical devices. She has represented a wide variety of clients ranging from individual inventors and start-up companies to universities, biotechnology companies and large pharmaceutical companies. Dr. McLaren has successfully prosecuted applications before examiners at the United States Patent & Trademark Office and supervised foreign counterpart filings around the world.

Dr. McLaren also counsels clients on strategies for obtaining various forms of intellectual property protection including trademarks, copyrights and trade secrets, and provides advice regarding contractual rights needed for the growth and protection of company assets, especially in the Life Sciences and Biotechnology industries. Her practice also includes rendering opinions of patentability, patent infringement, and patent validity.

Prior to forming the Life Sciences practice group at CRGP, Dr. McLaren practiced biotechnology law in the Intellectual Property group of Edwards Angell Palmer & Dodge, a national law firm, and previously in the Intellectual Property group at Akerman Senterfitt, a large Florida law firm. Dr. McLaren's legal practice was preceded by an extensive scientific career, highlights of which include a post-doctoral fellowship and subsequent medical faculty position at the University of Toronto, Canada, and medical faculty positions at McMaster University, Canada and the University of Miami, Bascom Palmer Eye Institute. Dr. McLaren has also founded two biotechnology companies, has served as a consultant to the ophthalmic pharmaceutical industry, and as a reviewer for peer-reviewed research grant applications and publications in scientific journals.



Navroze S. Mehta
President & CEO
NovaVision

Mehta brings more than 15 years of experience managing technology companies to his post at NovaVision. Mehta co-founded NovaVision, Inc. in the United States in 2002, guiding the company through the FDA clearance of its Vision Restoration Therapy (VRT) and securing its first round of funding.

Before joining NovaVision, he co-founded Dermdex, a medical technology company that specialized in practice efficiency solutions for dermatologists and plastic surgeons. Mehta

successfully managed the sale of Dermdex to Salu, Inc., a California-based, venture-backed company. Prior to co-founding Dermdex, Mehta was the president of Boca Global, a subsidiary of Boca Research where he was responsible for directing the day-to-day operations of a \$70 million NASDAQ company involved in developing Internet appliances and thin client and data communications solutions. Before joining Boca Research in 1998, Mehta was president and CEO of Comark Communications, Inc., a high-tech designer and manufacturer of television transmission systems and a wholly owned subsidiary of Thomson CSF, a \$7 billion global electronics company. Mehta received an MBA from Syracuse University and a Bachelor of Commerce degree from Sydenham College at the University of Bombay, India. He is a Certified Public Accountant (CPA) in the state of New York and a member of the Young Presidents Organization (YPO).

Stephen G. Nappi
Interim Director of Technology Transfer
Florida Atlantic University

Stephen Nappi played an integral role in the development of Florida Atlantic University's technology transfer program. After practicing technology transfer for over six years, he is now responsible for managing and marketing a portfolio of innovative technologies. Recently, he and a colleague started FAU's first Gap Fund Program to further develop inventions with the goal of increasing their commercial potential. Mr. Nappi serves as Chairman for the FAU Intellectual Property Committee, Technology Transfer Advisory Committee and Gap Fund Committee, and is a member of the Association of University Technology Managers. He received a Bachelor of Business Administration in 2002 with a double concentration in management and marketing from FAU and is currently pursuing a Master of Business Administration with a concentration in finance at FAU.

Mike Nicoletta
Executive Vice President
Metronic

Mr. Nicoletta, Executive Vice President in Medtronic's ENT and Neuro-Technologies business sector has been in the medical device and pharmaceutical industry for over 15 years. He has held numerous executive positions within the industry ranging from technical operations, R&D, project management, supply chain, information services and overall general management.

Mr. Nicoletta started his career with G.E. on their executive management training program and worked in several segments in the commercial, consumer and industrial markets. In 1991, he was recruited to the medical device and pharmaceutical industry by American Home Products where he devoted most



Innovation is our business.



The Florida Atlantic Research Parks of Boca Raton and Deerfield Beach offer high tech industries the potential for research and development partnerships with Florida Atlantic University.

ADVANTAGES

Two great locations in Boca Raton and Deerfield Beach have significant advantages for businesses locating in these dynamic research parks. Research park partners are able to interact with FAU's research community and take advantage of its facilities and expertise. Potential programs of mutual interest can include:

- Applied research directed at the industry partners' specific needs;
- Ability to utilize equipment and labs on a cost return basis;
- Availability of faculty and students to work for the industry partner on a part-time basis;
- Joint federal or private grant, and SBIR/STTR funding opportunities;
- Local venture and angel networks

In addition, FAU can develop customized educational programs, and industry partners' professional staff can participate in advanced degree programs. Join the 27 companies in the parks, and the 17 companies in our Technology Incubator.

For more information on how your high tech company can become involved in the Research Park, visit www.Research-park.org.



of his time running global operations. Mr. Nicoletta joined Medtronic in 2000 as the COO of their ENT and Ophthalmic Division and later became the Executive Vice President of the ENT and Neuro-Technologies business sector.

He has served on numerous community and civic affairs committees during his business career as well as an executive lobbyist for GE.

Mr. Nicoletta graduated from Murray State University with a degree in Business and currently resides in Jacksonville, Florida with his wife and children.



Art Pappas
Managing Partner
Pappas Ventures

Art has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He has assembled a team of investment, biotechnology and medical experts

who manage over \$250 million and oversee investments in more than 40 portfolio companies. Prior to founding Pappas Ventures in 1994, Art held senior level leadership positions at several multinational pharmaceutical companies. He was an executive member of the board of directors of Glaxo Holdings plc, for which he was responsible for international operations including research, development and manufacturing. Art previously was Vice President of Commercial Operations for Abbott International Ltd., and he held various executive operating positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. Among the companies for which he currently serves as a director are: AtheroGenics (Nasdaq: AGIX), which conducted a successful IPO in 2000, BrainCells and Genstruct. He was the founding CEO and is currently the chairman of CoLucid Pharmaceuticals.

Some of the firm's representative investments include Cerexa Pharmaceuticals (acquired by Forest Laboratories); Syntonix Pharmaceuticals (acquired by Biogen Idec); Peninsula Pharmaceuticals (acquired by Johnson & Johnson); Panacos Pharmaceuticals (Nasdaq: PANC); NuVasive (Nasdaq: NUVA); AtheroGenics (Nasdaq: AGIX); Gene Logic (Nasdaq: GLGC); Nuvelo (Nasdaq: NUVO; previously Variagenics); and Arena Pharmaceuticals (Nasdaq: ARNA).

Art is a member of the National Venture Capital Association (NVCA) Medical Industry Group Advisory Board. He previously served on the boards of Embrex (Nasdaq: EMBX), Quintiles Transnational and Valentis (Nasdaq: VLTS). Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and the

**Eckhard R. Podack, MD,
PhD**

**Professor and Chair of
Microbiology and Immunology
University of Miami Miller School
of Medicine**



Dr. Podack received his medical degree from the University of Frankfurt in 1968. He later received his medical license in 1970 in the fields of Internal Medicine, Surgery and Biochemistry. Upon completion of his medical license, he enlisted in the German Army where he was a Captain and battalion physician. After the army, he completed his PhD in the field of Biochemistry. From 1979-1984, Dr. Podack was honored with the Established Investigator Award from the American Heart Association. In 1987 he arrived at the University of Miami Miller School of Medicine where he serves as Professor of Microbiology and Immunology (primary) and Medicine (secondary). He has been Chairman of the Department of Microbiology and Immunology since 1994.

Peter Policastro, PhD

**Senior Director of Business
Development
The Scripps Research Institute**



Dr. Policastro is an entrepreneurial senior executive with extensive experience in launching and building successful businesses focused on early stage drug development and drug discovery platforms. He has specific experience in-licensing small molecule drug development programs from major pharmaceutical companies with subsequent advancement through IND filing and Phase I Clinical Trials and a proven ability to create attractive business plans from early stage assets and raise substantial venture capital. Dr. Policastro has demonstrated ability to bring together and lead exceptional management teams focused on developing and commercializing first in class drugs and discovery platforms that can successfully compete for major market opportunities. From December 2004 until his hire as Scripps Florida's Senior Director of Business Development in September 2006, Dr. Policastro was the Entrepreneur In Residence of BCM Technologies Inc, Houston, TX, a corporate seed stage venture capital firm funded by the Baylor College of Medicine to commercially advance emerging healthcare-related technologies and other assets under development by the faculty and other affiliated parties. From June 2002 until November 2004, he was the President/CEO of Sapphire Therapeutics (formerly Rejuvenon), one of BCM Technologies successful portfolio companies. At Sapphire, Dr. Policastro raised \$37 million Series B round from top tier venture capital firms to fund two potential first in class drugs through Phase II Clinical trials. Dr. Policastro has also served as President and CEO of oncology platform discovery

ALEXANDRIA INNOVATION CENTER

555 HERITAGE DRIVE, JUPITER, FLORIDA

NEIGHBORING THE SCRIPPS FLORIDA CAMPUS



ALEXANDRIA.



555 HERITAGE DRIVE, JUPITER, FLORIDA

THE ALEXANDRIA INNOVATION CENTER, neighboring the Scripps Florida campus, is a first-class scientific destination in the emerging Palm Beach County market. A magnet for entrepreneurial excellence, the facility offers flexible lease terms, turn-key office/laboratory suites of varying sizes, and shared support services, all of which are designed for the diverse needs of life science start-ups and emerging stage companies.

TENANT AMENITIES

- Enhanced mechanical, electrical and plumbing systems
- Capital financing and investment for tenants
- Full range of tenant services: laboratory design and construction, laboratory management and operations
- Emergency back-up power
- Expanded floor-to-ceiling heights
- Conference rooms
- Central glasswash facilities with autoclaves, washer/dryers, ice machine and RO/DI water stations
- Kitchenettes and break rooms
- High speed copiers with scanning
- Exercise and shower facilities
- On-site building management and support staff
- Raised loading dock area

DEVELOPER AND LANDLORD OF CHOICE TO THE LIFE SCIENCE INDUSTRY.

Alexandria Real Estate Equities, Inc. (ARE: NYSE), Landlord and Developer of Choice to the Life Science Industry®, the largest owner, cluster developer and pre-eminent first-in-class international real estate investment trust focused principally on the ownership, operation, management, redevelopment, selective development and acquisition of properties containing office/laboratory space. Alexandria is the leading provider of real estate to the life science industry, and has an outstanding ten-year track record as a NYSE listed company with an approximate \$5.2 billion total market capitalization (as of June 30, 2007). Alexandria provides high-quality real estate, technical infrastructure, services and capital to the broad and diverse life science sector. Client tenants include institutional (universities and independent not-for-profit institutions), pharmaceutical, biotechnology, medical device, life science product, service, bioenergy and translational medicine entities, as well as governmental agencies.

FOR ADDITIONAL INFORMATION CONTACT:

Patrick R. Kay
Director - Florida Operations
Alexandria Real Estate Equities, Inc.
1555 Palm Beach Lakes Boulevard
Suite 1208
West Palm Beach, FL 33401 USA
TEL: 561 683 5712
FAX: 561 683 5717
E-MAIL: pkay@labspace.com

company Enchira Biotechnology (formerly NASDAQ), Sr. Vice President of Plastics Manufacturing Company, a division of Borden Chemical, Senior Vice President and Chief Technology Officer of Plastics Manufacturing Company, a division of Sun Coast Industries, Inc. (formerly NYSE), and President of the U.S. research division of OctaNova Industries AB (Sweden). In 1992, he founded and served as CEO of Medgenesis, Inc., of Coral Springs, FL, which developed and manufactured disposable medical devices used in laser surgical procedures. Dr. Policastro started his career as a staff scientist at General Electric's Corporate Research Division in Niskayuna, NY where he was promoted to Program Manager, Specialty Polymers. Dr. Policastro is an inventor of 19 U.S. Patents and received his PhD in Organic Chemistry from The Massachusetts Institute of Technology and his Bachelors, Magna Cum Laude, in Chemistry from Duke University.



John C. Reed, MD, PhD
President & CEO
Burnham Institute for Medical Research

Burnham Institute for Medical Research is a non-profit biomedical research institute with nearly 750 employees, headquartered in San Diego, California, with major sites of operation in San Diego and

planned for Orlando, Florida. Dr. Reed received his undergraduate education from the University of Virginia (BA/Biochemistry), where he graduated Phi Beta Kappa in 1980, then entered the Medical School of the University of Pennsylvania (MD, PhD), where he graduated in Alpha Omega Alpha in 1986. Dr. Reed's residency training in Pathology & Laboratory Medicine was undertaken at the Hospital of the University of Pennsylvania, followed by post doctoral training in Molecular Biology at the Wistar Institute in Philadelphia. Dr. Reed was an Assistant Professor in the Medical School at U. Penn from 1990 to 1992, and served as a director of the Laboratory for Molecular 1 Diagnosis, performing DNA-based testing for clinical diagnosis at the university hospital. He also ran a basic-research laboratory, and was active in teaching residents, medical and graduate students.

In 1992, Dr. Reed joined the Burnham Institute, and was promoted to the Scientific Director position in 1995, prior to becoming President & CEO in 2002. He was chiefly responsible for recruiting and managing the scientific staff, quadrupling the number of researchers. Dr. Reed also conceived of and was instrumental in launching the formation of two new research centers at the Burnham Institute devoted to research on aging and neurodegenerative diseases (Dale E Webb Center for Neuroscience & Aging Research) and the institute's Infectious & Inflammatory Disease Research Center (IIDC). Dr. Reed also served as Deputy Director of the Burnham's NCI-sponsored Cancer Center from 1994 to 2002, and briefly as interim Director in 2002. He additionally holds adjunct Professorships at the University of California San Diego and

San Diego State University. Under Dr. Reed's direction, the Burnham is launching a 300 person East Coast expansion in Orlando, Florida.

Dr. Reed remains an active scientist, currently directing a laboratory of about 40 persons at Burnham, funded by less than \$5 million annually in competitive research grants. His research interests have focused primarily on cancer, but he has also made important contributions in the areas of AIDS, autoimmunity, stroke and other diseases. Dr. Reed has been a pioneer in delineating the fundamental mechanisms that regulate programmed cell death, a process by which cells in the body commit suicide through activation of a genetically controlled program. Much of his work has revealed how defects in programmed cell death contribute to diseases, resulting in novel strategies for therapeutic intervention. Dr. Reed is author of over 700 peer-reviewed scientific articles and over 50 book chapters. He has the distinction of having published more papers on programmed cell death (also known as apoptosis) during the decade 1992 to 2002 than any other scientist worldwide, according to the Institute for Scientific Information. Dr. Reed was also recognized by the Institute for Scientific Information as the world's most cited scientist in all areas of scientific inquiry from 1997 to 1999. Recently, Dr. Reed was recognized as one of the top 10 "Doctors of the Decade" for publication citations covering the decade 1995 to 2005, receiving more citations world wide than any other scientist in the field of "cell biology" and in the field of "general biomedicine." In 2007, Dr. Reed was chosen by the Achievement Rewards for College Scientists (ARCS) Foundation as their Scientist of the Year.

Dr. Reed leads several drug discovery efforts at the Burnham, including serving as director of the National Center for Chemical Library Screening based at Burnham (one of nine in the nation), and director of the Cancer Drug Discovery Group sponsored by the National Cancer Institute (NCI). His inventions have resulted in over 60 U.S. Patents or Patent applications, and have spawned drug-discovery programs at several biopharmaceutical companies. Dr. Reed's inventions in DNA-based targeting of genes in cancer have resulted in drugs that are currently undergoing Phase III clinical testing for patients with treatment-refractory cancers (Genasense).

Dr. Reed currently serves on the editorial boards of over 12 scientific journals. He has also served in various capacities as an advisor to the National Institutes of Health (NIH), American Cancer Society (ACS), and the American Association for Cancer Research (AACR). He is the recipient of numerous awards for his research accomplishments, and has been awarded over 70 research grants by a variety of funding agencies, including the NIH, ACS, Leukemia Society of America, CaPCURE, ABC2, and the Susan B Komen Breast Cancer Foundation.

Dr. Reed serves as an advisor and consultant to numerous biotechnology and pharmaceutical companies. Dr. Reed is the Scientific Co-Founder of three biotechnology companies, including IDUN Pharmaceuticals, a biopharmaceutical

company focusing on apoptosis-based therapies (acquired by Pfizer). He currently serves on the Board of Directors of ISIS Pharmaceuticals, Inc., Pharmion, Inc., STRATAGENE, Inc., BIOCOM, CONNECT, OSI Pharmaceuticals, Inc., BioDura, the California Institute for Regenerative Medicine (CIRM) and the San Diego Consortium for Regenerative Medicine. He is also a member of the Board of Trustees of Burnham. Dr. Reed has served on the Scientific Advisory Boards for IDUN Pharmaceuticals, Abbott Laboratories, Bristol-Myers-Squibb, ISIS Pharmaceuticals, Genta, GMP/Diagnostics, Stratagene, Structural Bioinformatics, Genome Biosciences, Entropia and Sun Microsystems.

Abel De La Rosa, PhD

**Senior Vice President
Business Development & Scientific Affairs
Pharmasset**

Abel De La Rosa has been with Pharmasset since December 2002 and is responsible for all out-licensing, in-licensing, corporate partnering and external scientific activities. From February 2000 to December 2002, Dr. De La Rosa held both scientific and business positions at Visible Genetics Inc., including Vice President of Product Development and Director of Strategic Marketing and Latin American Business. He was responsible for the development, transfer and improvement of products, including TRUGENE HIV-1 v1.0 Genotyping Test® and other sequencing-based assays for HCV and HBV. Dr. De La Rosa previously held positions at Innogenetics, Inc., Boston Biomedica, Inc., and Digene Corp. Prior to joining Digene, he completed two NIH Post-Doctoral Fellowships at the National Cancer Institute, an IRTA Fellowship in the Laboratory of Pathology and a Fogarty Fellowship in the Laboratory of Biochemistry. He is an inventor and author on several U.S. patents and publications relating to molecular diagnostic methods and techniques for infectious diseases and cancer. Dr. De La Rosa is a member of the board of directors of Research Think Tank, Inc., a privately owned infectious disease diagnostic and clinical research laboratory, and BioSouth, Inc., a company dedicated to the advancement of southern U.S. biosciences. Dr. De La Rosa received a BA in Microbiology from the University of California, San Diego, and a PhD in Microbiology from Miami University.



Mel Rothberg

**President & CEO
Rothberg Associates**

Mel Rothberg has over the last 30 years participated in the development of the South Florida bioscience industry. He has held executive positions in the medical device, information technology and biopharmaceutical sectors.

Currently he is Chairman and

CEO of Advanced Processing and Imaging, CEO of Dharma Biomedical, CEO of Rothberg Associates, Inc. and a member of the Board of Directors of Lotus Pharmaceuticals, Inc.

(LTUS.OB). Previously he was Executive Vice President, Operations of Viragen Inc., Plantation, Florida (VRA: AMEX) and Director of Viragen International Inc. (VGNI: OTCBB) and Viranative AB (Sweden) where he was responsible for manufacturing, regulatory, business development, marketing and sales of Viragen's lead drug Multiferon. Prior to Viragen, he was Vice President of Manufacturing and Business Development for Althin Medical a Swedish publicly traded company focused on the hemodialysis machine and disposables market. He previously held multiple roles with Dow Chemical and Cordis Dow and was instrumental in selling Dow's dialysis division to Althin Medical. He held both international and domestic positions within Dow's subsidiary CD Medical including responsibility for offices in Australia, Singapore and Japan and was Managing Director of Cordis Dow's European manufacturing operations located in the Netherlands. He was instrumental in developing one of Dow Chemical's first biotechnology businesses in the use of hollow fibers for cell culture and holds a patent for the "Growth of Cells in Hollow Fibers in an Agitated Vessel". Additionally he developed and holds a patent on the "Process of Making a Cellulose Acetate Semipermeable Membrane" for the use as a hemoconcentrator in open heart surgery.

He was instrumental in forming BioFlorida's South Florida Bioscience Consortium, a collaborative regional effort that supports the commercialization of bioscience products and the development of the bioscience industry in South Florida (Broward, Miami-Dade, Palm Beach Counties and the Research Coast). His efforts assisted in the establishment of the South Florida Bioscience Consortium as the "one voice" within the region and is supported by the economic development agencies (Broward Alliance, Beacon Council, Business Development Board of Palm Beach, iCoast and the Economic Development Corporation of South Florida) and the academic/research institutions (University of Miami, Florida International University, Nova Southeastern University, Florida Atlantic University, and Palm Beach Atlantic University). Rothberg was the recipient of the 2007 Greater Miami Chamber of Commerce Healthcare Hero's Award in the Biomedical category.

He graduated from Vanderbilt University with a Chemical Engineering degree and has an MBA from Nova Southeastern University. He was recently appointed to the Broward Workforce Development Board and is a member of the South Florida Regional Leadership Council. He is a member of the American Institute of Chemical Engineers, North American Membrane Society, American Association of Blood Banks, Licensing Executive Society, Association of University Technology Managers and currently serves on the BioFlorida Board of Directors, iCoast Board of Directors, Florida International University Biomedical Engineering Advisory Board, Nova Southeastern University School of Dentistry Board of Councilors and has previously held committee positions within

the Biotechnology Industry Organization's Investor Relations Committee, Patient Advocacy Committee and Business Development Committee. Other past memberships included the Center for Health Technologies, Executive Board Member, Greater Miami Chamber of Commerce One Community/One Goal-Biomedical Task Force Member, Enterprise Florida Health Technology Task Force Member, and as a lay member of the Florida Bar Grievance Committee 11F.



Boris N. Reznik, PhD
Chairman
bioRASI

bioRASI serves the biotech and pharmaceutical industries by focusing on translational clinical development of small molecule drugs, biologics and medical devices. Leveraging its unrivaled worldwide scientific resources and its unique Program Opti-

mization™ approach bioRASI accelerates the development and approval of innovative as well as generic and 505(b)(2) therapeutics.

In his twenty five years in the technology industry, Dr. Reznik has participated in almost everything the industry can offer: founding and leading successful high-tech companies, IPOs and M&As, bubbles and bursts. As a visionary, leader and manager, Dr. Reznik has pioneered such concepts as venture development, guided entrepreneurship and rapid prototyping of therapeutics.

Dr. Reznik brings excitement and passion to every one of his undertakings and has been a featured speaker in Venture and Industry conferences and symposia worldwide. Dr. Reznik has authored a number of patents and publications and earned his PhD from the Russian Academy of Sciences.



Stanley Satz, PhD
President and Chief Scientific Officer
Bio-Nucleonics

Stanley Satz, PhD, a former educator, scientist and physicist, is President and Chief Scientific Officer of Bio-Nucleonics, Inc. The company's mission is to develop and market molecular imaging agents and medical

devices capable of advancing and improving management of significant chronic human diseases at the earliest stage. Satz founded Bio-Nucleonics after leaving Mount Sinai Medical Center of Miami Beach and the University of Miami. A University of Miami graduate, he is Chairman of the Research Advisory Board at Florida Atlantic University, and is on the Board of Directors of the U.S. Industry Coalition, and Cygene Inc., a biotechnology company. Satz has authored a number of

journal articles and holds five medically related U.S. patents.

Satz co-developed and obtained U.S. Food and Drug Administration approval of Strontium Chloride Sr-89 Injection. Bio-Nucleonics is marketing this therapeutic radiopharmaceutical used for the relief of cancer bone pain arising from metastatic prostate and breast cancer. Benefits of this cost-effective therapy are improved quality-of-life and reduction and/or elimination of the need for narcotic analgesics such as morphine. Strontium Chloride Sr-89 Injection is reimbursed by Medicare and by most insurance carriers, and is the first in a series of complementary generic radiopharmaceuticals and proprietary molecular imaging agents for detection of cardiovascular, oncological and neurological diseases. Bio-Nucleonics traces its successes in drug and medical device development to receiving a number of research and development grants from Enterprise Florida, NATO, the National Institutes of Health's Small Business Innovative Research Program (SBIR), and the Advanced Technology Program (ATP) of NIST.

In 2007, the Company received FDA marketing clearance for the Gynocyte®, a single-use brachytherapy device for treatment of gynecological and cervical cancers. This product, developed in collaboration with Dr. Aaron Wolfson of the University of Miami Sylvester Cancer Center, is the first new advancement in low-dose rate brachytherapy treatment in 20 years, and is revolutionizing treatment and success rates. Cervical cancer is the number two cause of cancer deaths among women, after breast cancer. Over 25 percent of women between the ages of 14 and 59 are infected with the human papilloma virus (HPV). Around 2% of these women will get cervical cancer and with treatment, many will survive and live normal, healthy lives.

Kelly L. Smallridge
President
Business Development Board of
Palm Beach County




Upon employment in 1988, Ms. Smallridge served in the Membership Department where she managed all private funding for this not-for-profit economic development organization. In a five-year period, the total budget went from \$535,000 to \$1.8 million and membership set a record high of 500 top private businesses.

From 1993-98, Ms. Smallridge worked in the Existing Industry and Retention Department for the Business Development Board. Her role was to facilitate the expansion of existing Palm Beach County companies by connecting them to available real estate, tax abatements, housing and labor costs, grants and incentives. In 1998, Ms. Smallridge received her Master Consultant Certification from Business Retention and Expansion International.



PHASE 3 PROPERTIES

EFFECTIVE LIFE SCIENCE FACILITIES



Phase 3 Properties, Inc. is proud to be a part of the progressive energy fueling the Florida Life Science community onto the center stage of the bioscience industry.

Phase 3 Properties is a modern private equity biotech real estate development firm dedicated to the growth of the life sciences in Florida.

For more information contact:
Warner Bonner, Principal
PHASE 3 PROPERTIES, INC.
T: (858) 546.0888
F: (858) 546.0999
bonner@phase3properties.com



Flexibility by *design*.

Any CMO can *claim* they're flexible.
Our organization was planned that way from the start.

The design of our organization allows us to get your biopharmaceutical from bench to clinic on time and at reasonable prices.

Our flexibility allows us to meet your needs for:

- **Scheduling**
- **Budgeting**
- **Production scale**

We offer a wide range of services including:

- **Process development**
- **cGMP manufacturing**
- **Sterile fill and finish**
- **Quality Control and Quality Assurance**
- **Cell banking**



13702 Innovation Drive • Alachua, Florida 32615

©2008 Florida Biologix

Contact person: Nicole Coelho
Name of Institution: University of Miami
Address: 1475 NW 12th Ave, suite 2012
Phone: (305) 243-5689
Fax: (305) 243-3510

BioFlorida Conference

UM Innovation is comprised of the Office of Technology Transfer, the Wallace H. Coulter Center for Translational Research and the future Life Science Park and facilitates rapid advancement of early stage technologies. Our key areas for technology commercialization are ophthalmology, cancer, neuroscience, orthopedics and cardiovascular. The Wallace H. Coulter Center also serves as a biotechnology incubator and provides internal "venture capital".

A few of the key products that have emerged are 1) Rapid Tissue Processor for histopathology, 2) monoclonal antibody to treat non-Hodgkin's lymphoma, 3) iontophoretic drug delivery device for ophthalmology, and 4) a novel therapeutic for dry eye syndrome.

MILLER
 GROUP OF MEDICAL
 SUPPLIES

UNIVERSITY OF
Miami

Put our experience to work for you



www.eoslifesciences.com

Eos Lifesciences is a specialty Clinical Development Organization with focus on Phase I –III (target focus on IIa) clinical trials, servicing primarily Biotech and small to mid-size pharmaceutical companies. Our team has worked together for several years and has been involved with 12 NDAs in a wide range of therapeutic areas and indications. Our capabilities include: Project Management, Monitoring, Medical Services, Clinical Data Management, Biometrics and Medical Writing.

OMNICOMM SYSTEMS | *First in Functionality™*
 EDC/CLINICAL TRIAL MANAGEMENT

www.omnicomm.com

OmniComm Systems, Inc. provides customer driven electronic data capture (EDC) solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance.

- cGMP Production Facilities
- R&D Laboratories
- Cleanrooms
- Renovations to Operating Facilities
- Pilot Plants
- Nanotechnology Facilities
- Vivarium
- Bioprocessing Facilities
- High-Containment Labs
- Medical Device Facilities




WT

The Whiting-Turner Contracting Company
 Tampa - Orlando - Fort Lauderdale
 Nationwide
www.whiting-turner.com

In 1998, Ms. Smallridge was promoted to Senior Vice President of Operations where her duties included management of all administrative functions, department strategic plans, budget and the overall operations of the organization. In addition to her responsibilities with the Business Development Board, she has also played an active role in the organization of the InternetCoast, a tri-county effort to brand South Florida as a global technology hub.

Ms. Smallridge is also responsible for Palm Beach County's most successful public/private partnership in education called PACE (People, Available, Committed and Employed.) PACE created several major programs aimed at enhancing the public schools within Palm Beach County. The "Teacher-to-Work" program places 100 high school teachers in a private business for a day and the Annual PACE luncheon provides 100 high school students with the opportunity to meet with local CEOs to discuss internships and employability skills. Ms. Smallridge serves as the coordinator for this initiative.

A native of West Palm Beach, Ms. Smallridge continues to participate in various charitable organizations and committees including the American Cancer Society, Young Friends of the Kravis Center and Susan B. Komen Cancer Foundation. Kelly, and her husband, Mark reside in Wellington with their 3 sons, Grant, Cole and Rhett. For the past three years, Kelly has donated a tremendous amount of time to the school they attend serving on several committees.



David Seo, MD
Associate Professor of
Medicine Division of
Cardiology and Interdisciplin-
ary Stem Cell Institute

Dr. Seo received his BS and MD degrees from Duke University. He completed his internal medicine residency at Beth Israel Deaconess Medical Center of Harvard Medical

School. He did his cardiology training at Duke University Medical Center where he also completed a research fellowship in cardiovascular genomics in the laboratory of Dr. Pascal Goldschmidt. After completing his fellowship training, he served as a faculty member in the division of cardiology and the Institute for Genome Sciences and Policy at Duke. Dr. Seo arrived at the University of Miami Miller School of Medicine in April of this year and serves as a faculty member in the division of cardiology and the Interdisciplinary Stem Cell Institute. He is also the Director of the Genomic Medicine and Biorepository Program for the school of medicine. Dr. Seo is a practicing general cardiologist. His main research interests are in cardiovascular biomarker discovery and stem cell mediated vascular repair.

Paul C. Schiller, PhD
Director, Adult Stem Cell Program at the GRECC-VAMC
University of Miami Miller School of Medicine

Dr. Schiller received his BSc at Universidad Cayetano Heredia in Lima, Peru, and his PhD in the Department of Biochemistry and Molecular Biology at University Miami Miller School of Medicine in 1987. He became faculty at University of Miami in 1989.

Sondra Smyrniotis
Founder and CEO
Eos Lifesciences



Sondra Smyrniotis, MSc, Founder & COO of Eos Lifesciences has spent over 13 years in the pharmaceutical industry. Prior to joining Eos, Ms. Smyrniotis was Executive Director of Clinical Operations at Kos Pharmaceuticals, which was acquired by Abbott Laboratories in December 2006. Ms. Smyrniotis joined Kos in 2004 and was responsible for the clinical operations, monitoring, and training functions, which included clinical process and organizational re-engineering. In 2005, Ms. Smyrniotis was personally selected by the President and CEO of Kos Pharmaceuticals to receive the Kos Values "President's Award" for outstanding contribution. From 1999 until 2004 Ms. Smyrniotis served as Director, Clinical Research at Sanofi-Synthelabo Canada and was also appointed Clinical Research Network Leader for North America, and Internal Oncology Therapeutic Correspondent. In this dual role, Ms. Smyrniotis oversaw North American operations and was global operations lead for the oncology franchise. Prior to joining Sanofi, Ms. Smyrniotis spent 5 years in the pharmaceutical industry with Eli Lilly and Janssen-Ortho in international clinical research roles.

Ms. Smyrniotis earned her BSc in 1991 from Concordia University and 1993 earned her MSc in Teratology from McGill University in Montreal, Quebec, Canada.

Richard O. Snyder, PhD
Director
Florida Biologix



Is the Director of Biotherapeutic Programs and Director of the Center of Excellence for Regenerative Health Biotechnology at the University of Florida. He is also a faculty member in the Department of Molecular Genetics and Microbiology, and Department of Pediatrics in the College of Medicine. His efforts are focused on pre-clinical and first-in-man studies for the development of biotherapeutics. In addition, he oversees education and training programs in industrial biotechnology for high school and college students, and the workforce. He has also been directly involved in the design, construction, and equipping of biopharmaceutical pilot plants. Prior to joining the faculty at UF, Dr. Snyder was an Assistant Professor of

Pediatrics at Harvard Medical School, and was previously employed by Cell Genesys, Somatix, Merlin, and Avigen where he was engaged in the development of gene transfer vector and vaccine technology, along with therapeutic applications. Dr. Snyder was a postdoctoral fellow at Johns Hopkins University School of Medicine, received his doctoral degree in Microbiology from The State University of New York at Stony Brook, and obtained his B.A. in Biology from Washington University in St. Louis. Dr. Snyder is on the Editorial Board of the Journal of Gene Medicine and Current Gene Therapy, and has authored over forty publications describing virus biology, viral vector development and manufacturing, and gene transfer. He serves on statewide, national, and international advisory committees.

of the Board of Trustees of the Tavistock Foundation, Board of Directors of the UCF Foundation and Board of Directors for BioFlorida.

Marsha Thrower
Grants Manager
Workforce Alliance

In this position she is responsible for grants research, grant development, project management and evaluation of grant-funded initiatives. Prior this position, Ms. Thrower served as a principal, Personnel Director, and Director of State and Federal Programs and Student Services for a large urban school district in the Midwest. Subsequently she founded and operated for fourteen years a professional consulting firm providing planning, grant development, and evaluation services for governmental units, educational institutions, and nonprofits working in education, health, human services, housing, substance abuse and youth development. Clients included the University of Michigan, the Michigan Department of Community Health, the W.K. Kellogg Foundation, the C.S. Mott Foundation, several community colleges, community foundations, municipalities, school districts and charter schools.

Ms. Thrower received her Bachelor's Degree from Michigan State University, Master's Degrees from both Michigan State University and Eastern Michigan University and pursued a doctoral degree from Michigan State, all focused on Education and Public Policy.

Special interests include struggling teens and parents, as well as the emotional growth schools, programs, and services that support them.

Thomas Tremble
Associate Vice President of
Government and Regional Affairs
Advanced Medical Technology
Association (AdvaMed)

Thomas Tremble is responsible for state government relations and liaison with state and regional device groups. In directing the state program, he works closely with the state affairs committee to identify, track, and influence priority legislation that would impact patient access to medical technology. Among issues that he is involved with are technology assessment, treatment guidelines, and marketing restrictions. He has also played a major role in the association's involvement in state health care reform, clinical laboratory licensure, facility licensure, and product liability.

In addition to state government relations, he played a key role in establishing the association's political action committee, and has also been involved in activating grassroots advocacy on key federal issues.

Kim Tesch-Vaught
Senior Director Work Force
Gainesville Area Chamber of
Commerce
FloridaWorks Business Services

Tesch-Vaught has been with the Chamber since July of 2000, having also managed the Leadership Gainesville, Florida Community Design Center, and Inter-City Visit programs. An active member

of the community, Kim serves on the LifeSouth Community Advisory Board and is the current president of the Leadership Gainesville Alumni Association. Kim holds a Bachelor of Science in Education and Social Policy from Northwestern University and is a graduate of the United States Chamber of Commerce Institute for Organization Management. She and her husband Tim Vaught have two children, Reme and Jonathan.

Rasesh Thakkar
Senior Managing Director
Tavistock Group

Rasesh Thakkar is senior managing director of Tavistock Group and a member of the board of directors. Sesh focuses on corporate finance and structure, mergers and acquisitions, and strategic planning for the Group. He helps determine overall strategy, targets

sectors for investment, negotiates acquisitions and sales, and transitions acquisitions into the Group's holdings. He has lived in the United States, South America and Europe on behalf of the Group and was previously an agent with the IRS. Sesh holds a BSBA (hon) in accounting from the University of Central Florida. Currently, he serves on the Board of Trustees for the Greater Orlando Chamber of Commerce, the Governors Council of the Metro Orlando Economic Development Commission and is Chairman of the Board of Governors for M.D. Anderson Cancer Center Orlando. Sesh is also a member



Prior to coming to AdvaMed, he worked in the U.S. Senate for the Select Committee on the Iran-Contra Affairs and the Arms Control Treaty Office, where he worked with committee staff reviewing the intermediate nuclear forces treaty with the Soviet Union. He also worked as a Legislative Assistant in the Maine Legislature. He is a graduate of the University of Maine with a B.A. in Political Science.



Claes Wahlestedt, MD, PhD

**Professor, Director of Neuroscience Discovery
The Scripps Research Institute
Scripps Florida**

Dr. Wahlestedt earned his MD and PhD degrees from the University of Lund (Sweden) in 1984 and 1987, respectively. After post-doctoral training

at Kyoto University, Japan, and at Georgetown University, Washington DC, USA, he took a position as Assistant Professor at the Department of Neurology and Neuroscience, Cornell University Medical College in New York City.

He was then recruited to the pharmaceutical industry and from 1993 to 1997 Dr. Wahlestedt served as (founding) Head of Astra-Zeneca Research Center in Montreal, Canada. With a focus on drug discovery for brain disorders as well as pain, he grew this Center to over 100 scientists. In Montreal, he was also an Adjunct Professor at McGill University.

In 1997, Dr. Wahlestedt was appointed Professor and started the Center for Genomics and Bioinformatics at the Karolinska Institute in Stockholm (Sweden) and hired some 150 scientists over the following several years. This Center (and academic Department) was established in close collaboration with Pharmacia & Upjohn (later part of Pharmacia Corp. and Pfizer Inc.), and Dr. Wahlestedt remained an employee of these companies from 1997 to 2004, serving on various R&D leadership teams.

In 2005, he joined the new Scripps Florida (Jupiter, FL) as Professor and Director of the Neuroscience Discovery (CNS Disease) Program. In addition to the drug discovery work relating to neurological and psychiatric diseases, his current research focuses on basic aspects of regulatory RNAs as well as on human genome variation.

Since 2004, Dr. Wahlestedt is also an Adjunct Chief Scientist of Genomic Sciences at the Japanese national research institute, RIKEN, in Tokyo and Yokohama.

In addition to his experience from over a decade as a senior manager in the pharmaceutical industry, Dr. Wahlestedt has served on boards of a number of smaller biotech companies.

Bill M. Wardell, MD PhD

**President
Wardell Associates International**

A large part of Wardell's consulting includes solving problems in Drug Development, Regulatory Approval and Safety, for both large Pharma companies and small startups in biotech, drugs, and some devices.

Bill Wardell's Pharmaceutical and Biotechnology industry experience includes: President, Protein Engineering Corporation (now Dyax); Senior-VP, Drug Development, Parke-Davis; VP-Medical Director, Boehringer Ingelheim Pharmaceuticals; Senior Scientific Officer at Covance, and Executive Director of the Covance Institute for Drug Development Sciences. He serves on two Corporate Boards (OrthoLogic, Inc., and PhytoCeutica, Inc.), several Scientific Advisory Boards, and the Board of the American Board of Clinical Pharmacology.

Prior to Industry, his academic and clinical career was mainly at the University of Rochester Medical Center, as Associate Professor of Pharmacology, Toxicology and Medicine, attending on the Clinical Pharmacology consultation service of Strong Memorial Hospital. He co-founded and directed the University's Center for the Study of Drug Development (now at Tufts). He has testified as an expert in Drug Development in several Congressional hearings.

In addition to drug discovery and development and its contribution to medicine, his interests include medical devices, clinical pharmacology, clinical trial methodology drug safety, regulation, biotechnology, pharmacogenomics and botanicals — topics on which he has published over one hundred scientific papers and four books.

Bill Wardell earned his MA, PhD (in pharmacology), and MD at the University of Oxford (UK), and was a Merck International Fellow in Clinical Pharmacology and Medicine under Dr. Louis Lasagna at the University of Rochester / Strong Memorial Hospital.

Michael Wasserman, PhD

**Associate
H.I.G. Ventures**

Michael focuses on investments in therapeutics and medical devices. He is involved in all stages of the investment process and currently serves as a board member or observer for H.I.G. portfolio companies HyperBranch Medical Technology, Transzyme Pharma, CardioFocus, and Metastatix.

Prior to joining H.I.G., Michael was a Principal at Innovations Foundation, a firm focused on the creation, financing and growth of high technology companies in the life sciences, information technology and engineering sectors. At Innovations



Foundation, Michael was instrumental in building multiple high growth companies based on technology derived from academic or federally sponsored research programs.

Michael has also held prominent operating roles in several entrepreneurial and venture-backed life sciences companies, including CELLutions Biosystems, where he served as Vice President, Business Development. At CELLutions, Michael broadly managed business operations and was directly responsible for the successful negotiation of multiple partnership, co-development and licensing agreements deals with industry leading pharmaceutical and biotechnology organizations. Earlier in his career, Michael worked directly for, or as a consultant to, corporate finance institutions, pharmaceutical companies and clinical research organizations.

Michael received his BSc from McGill University and his PhD from the University of Toronto.



Rhys L. Williams
President
iTherapeutics
StromaCyte

iTherapeutics is a biotechnology company which develops RNAi therapies for retinal degenerative disease, and StromaCyte is a discovery biopharmaceutical venture focusing on reconstituting the responsive immune system.

Both firms were co-founded with prominent faculty from Scripps Florida and the University of Miami. Mr. Williams is also President of New World Angels, Inc., a member-managed angel investment group based in the Miami-Ft. Lauderdale-Palm Beaches region. His prior business experience includes roles as a venture capitalist with SI Ventures (GarnerGroup affiliated fund), finance and legal executive with Ixion Biotechnology, financial consultant with Smith Barney, and operations supervisor with American Express. He serves the Boards of the University of Florida's Center for Entrepreneurship and Innovation, Leadership Florida (Florida Chamber of Commerce affiliate), South Florida Science Museum (Palm Beach County)(Chairman-Elect). He is also an advisor to Ocean Ridge Biosciences and co-chair of the underwriting committee for the JFK Medical Center Foundation. He is a member of BioFlorida, the Economic Council of the Palm Beaches, the Business Development Board of Palm Beach County, the Harvard Club of the Palm Beaches, and Florida Blue Key. He earned his bachelor's degree from Harvard College magna cum laude and both MBA and J.D. degrees from University of Florida, where he served as MBA class president as well. He is admitted to the Florida and New York Bars and speaks Spanish and basic Portuguese. A military veteran, his 14 years of active and reserve component service included command of an Army Special Forces combat diver detachment and deployments to Latin America. A fifth generation South Floridian, Rhys lives in Delray Beach with his wife Dr. Lorna Sohn Williams and their two children.

Brenda Workman

**Director of Business Retention,
Life Sciences, and Manufacturing
Enterprise Florida**



Enterprise Florida is a public-private partnership responsible for leading Florida's statewide economic development efforts. Workman served previously as the Director of Central City Development for the Greater Oklahoma City Chamber where she was the lead for life science business recruitment for the Presbyterian Health Foundation Research Park, in partnership with the University of Oklahoma Health Sciences Center and the OU Medical Research Foundation. She also was Director of Site Evaluation for the Kentucky Cabinet for Economic Development and the Director of Business Decision Support Services for the South Carolina Appalachian Council of Governments. Brenda has a BS in Finance and MBA from the University of South Carolina, and is working toward an Ed.D. in Organizational Leadership at Nova Southeastern University in Fort Lauderdale, FL.

Brenda has earned the Certified Economic Developer (CEcD) designation from the International Economic Development Council. Projects led by Workman have won the International Economic Development Council (IEDC), 2005 Special Website award, the 2005 CoreNet Global Economic Development Leadership and Accomplishment Award, and was a finalist for the 2003/2004 e-Business Stockholm Challenge Award, selected out of 900 projects submitted from 107 countries. This award is considered the "Nobel Prize for Information Technology society."

Bin Yan, PhD

**Director of Business Development
Wallace H. Coulter Center for
Translational Research
University of Miami**



Dr. Yan serves as Director of Business Development, WHCC, responsible for transferring and capitalizing on UM/WHCC's intellectual property. Prior to joining the University of Miami, she held various positions with different university technology transfer offices where she worked with academic researchers, industry and government to protect and commercialize university research results. She holds a PhD from the University of Florida where she specialized in mitochondrial gene expression, and a law degree from the University of Saskatchewan, Canada.

Nicholas Zachariades, PhD

Patent Agent

Akerman Senterfitt

Dr. Zachariades has an extensive background in the fields of molecular genetics, immunology, and virology including level 4 viruses. His work focuses on assisting clients in the various aspects of patent law in the areas of biotechnology, small molecules, vaccines and oncology. Some of Mr. Zachariades' patent projects include many new and cutting edge technologies in the fields of virology, immunology, genetics, molecular genetics, molecular immunology, bioinformatics, biochip arrays - DNA and protein chips and chemical patents.

He co-authored scientific publications in Cell, Journal of Immunology, Cellular Immunology and Emerging Infectious Diseases, and has presented and lectured on the topics of immunology and virology.



Redefining your
chemical supply chain


1 (800) 450 - 3435

www.doeingalls.com

SOUTHERN RESEARCH

Legendary Discoveries. Leading Innovation.

...discovering and developing
therapeutics to fight cancer and
combat infectious diseases



Drug Discovery

Scientists at Southern Research discovered 6 of the FDA-approved cancer drugs currently on the market and another 6 in late-stage nonclinical or clinical development.

Drug Discovery Partnerships

- Proprietary Libraries
- High Throughput Screening
- Assay Development
- Medicinal Chemistry Services

Nonclinical Drug Development

Contract Research Capabilities

- Cancer Efficacy Models
- Angiogenesis Models
- Infectious Disease Models
- Clinical Trials Support
- Bioanalytical Services
- ADME/PK
- Toxicology

SOUTHERN RESEARCH

Birmingham, Alabama

888.322.1166 | 1.205.581.2830

BusDev@SouthernResearch.org

www.SouthernResearch.org



When Tom Webb was planning for an expansion to a major pharmaceutical campus, he knew that continued operations and an accelerated project schedule were essential to the overall mission of bringing new products to market. The client’s business demanded that timelines be met without fail. Assembling a hand-picked team of experienced construction professionals, Tom and his crew divided the project into a series of overlapping phases, which allowed existing labs to operate uninterrupted, while construction continued right next door on others. As a leader in life sciences construction, Skanska is a committed partner, working seamlessly with clients to deliver customized solutions for projects of all sizes and complexities.

www.skanska.com

SKANSKA

Over 40 Years Experience In The Promotional Products Industry

- Tradeshow giveaways
- Corporate gifts
- Officeware, drinkware, etc.
- Outstanding customer service
- Creative ideas and products
- Complete e-commerce capabilities for your company’s online store!

Contact Terry Arke at:
1-800-446-7204 x119
terrya@jsapromos.com

Jacksonville Specialty Advertising

Don't forget to call Terry about your BioFlorida membership discount!!!



Fostering the growth of university-affiliated biotech companies with facilities, resources, and an entrepreneurial environment.



What is Florida BioDatabase™?

An exciting new resource with the latest information on Florida’s bioscience industry plus unique profiles of biotechnology and biomedical device companies. The University of Florida’s Sid Martin Biotechnology Incubator is publishing this free, web-based database in support of the biotech industry statewide.

Who Will Use It?

Media, investors, potential strategic partners, service providers, customers, economic development entities, researchers and others will find this a valuable resource.

What Companies are Included?

Florida companies that use modern biological techniques to develop products or services for human health care or animal health care, agricultural productivity, food processing, renewable resources, industrial manufacturing, or environmental management are included.

www.biotech.ufl.org

12085 Research Drive ~ Alachua, FL ~ 32615 • 386.462.0880



Discover your future.

Life is one grand experiment where you control all the variables. At Nova Southeastern University, you'll be exposed to an endless array of options, and the opportunity to participate in world-class research in a variety of disciplines including medicine, dentistry, optometry, pharmacy and oceanography. With \$45 million in research grants and state-of-the-art facilities and equipment, NSU is an amazing place to find yourself.



www.nova.edu

Ft. Lauderdale (Main Campus)

800-541-NOVA



Clearly not apples to apples. When it comes to choosing a news wire, there's no comparison.

Business Wire has decades of experience counseling clients on the best strategic approach for communications, and on how to anticipate and satisfy regulatory concerns. Our technology sets the standard for the industry and continues to be at the forefront of innovation. We have more full-service newsrooms around the world and our editors are renowned for their painstaking attention to detail. Why pick anyone else? **Better solutions. Better be Business Wired.**

Business Wire
A Berkshire Hathaway Company
Call our experts at 888.381.WIRE or visit us at BusinessWire.com
©2007 Business Wire, the Business Wire logo, and Business Wired are trademarks of Business Wire, a Berkshire Hathaway company.

99 out of 100
Doctors Agree...



design :: web :: pr :: print :: synergy

3400 Powerline Road • Fort Lauderdale, Florida
P: 954.239.9733 • F: 866.273.9427
www.4fsm.com



Boston • Providence • Washington, DC • West Palm Beach

Compass Strategies, LLC is a government relations firm specializing in the life sciences. Our clients include diagnostics manufacturers, hospitals and biopharmaceutical companies.


Unlike traditional lobbying firms, that merely “open the door” for clients, Compass Strategies is process-oriented and is focused on providing our clients with a return on their investment.


It is our people and our approach that has made Compass Strategies, LLC one of the nation’s fastest growing government relations firms.



www.compassstrategies.com

Contact:
Joseph G. Penkala
Compass Strategies, LLC
777 South Flagler Drive
West Tower, Suite 800
West Palm Beach, FL 33401
Tel: (561) 805-9111
E-mail: jpenkala@compassstrategies.com





We're also:

15,000 antibodies

2483 enzymes

718 electrophoresis reagents

329 growth factors
and cytokines

You're hot on the trail of the next big breakthrough.
And too busy to spend time searching for the right tools.

We offer them all. From **nucleic acid purification kits** to **PCR reagents**, from **apoptosis antibodies** and kits to **signal transduction tools**. Growth factors, gene expression kits, gel boxes and everything in between.

Oh yes, beakers and tubes too. We call it breadth of product.
You'll call it the joy of one-stop shopping.

Fisher Scientific. One Source. Infinite Solutions.

Find out how we can simplify
your life science processes at
fishersci.com/lifescience or
call Fisher Customer Service
at 1.800.766.7000
to request the
**Custom Life Science
Services Folder**

What we accomplished last year is a really big deal.

Actually, two big deals. Two of the biggest life sciences deals of the past year, in fact. One of our privately-held portfolio companies, Cerexa, was acquired by Forest Laboratories for \$483 million in cash plus a potential \$100 million milestone payment. And Plexikon entered into a partnership with Roche that could result in Plexikon receiving upwards of \$700 million in development and commercial milestone payments. Now, we can't claim to be involved in deals this big every day, but over the past decade we're proud to have guided the successful development of more than 40 life sciences companies. And that's no small feat.



www.pappasventures.com